

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/164949/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Frei, Oleksandr, Hindley, Guy, Shadrin, Alexey, van der Meer, Dennis, Akdeniz, Bayram, Hagen, Espen, Cheng, Weiqiu, O'Connell, Kevin, Bahrami, Shahram, Parker, Nadine, Smeland, Olav, Holland, Dominic, Schizophrenia Working Group of the Psychiatric Genomics Consorti, de Leeuw, Christiaan, Posthuma, Danielle, Andreassen, Ole, Dale, Anders and O'Donovan, Michael 2024. Improved functional mapping of complex trait heritability with GSA-MiXeR implicates biologically specific gene sets. *Nature Genetics* 56 , pp. 1310-1318. 10.1038/s41588-024-01771-1

Publishers page: <https://doi.org/10.1038/s41588-024-01771-1>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



SUPPLEMENTARY NOTE 1.

The GSA-MiXeR model

Assuming a simple additive genetic model, a quantitative phenotype $y \in \mathbb{R}$ is modeled as a linear combination of genotype dosages g_i with weights β_i :

$$y = \sum_{i=1}^{\bar{M}} g_i \beta_i + \epsilon_y ,$$

where the index i runs over \bar{M} genetic variants, weights $\beta_i \in \mathbb{R}$ are known as *additive effects of allele substitution*, and the $\epsilon_y \sim N(0, 1 - h^2)$ term is a normally distributed residual, which reflects contributions from the environment and non-additive genetic effects. The quantitative phenotype y is assumed to be centered and scaled, $E[y] = 0, \text{Var}[y] = 1$, implying that the variance $\text{Var}[\sum_i \beta_i g_i]$ is equal to each trait's SNP heritability, $h^2 \in [0, 1]$. Genotype dosages g_i are assumed to be centered but not scaled, i.e., $g_i \in \{0 - 2f_i, 1 - 2f_i, 2 - 2f_i\}$, where f_i is allele frequency of the i -th variant.

In the GSA-MiXeR model, we postulate a spike-and-slab prior on β_i :

$$\beta_i \sim (1 - \pi_1) \delta_0 + \pi_1 N(0, \sigma_i^2) ,$$

where the $\pi_1 \in [0, 1]$ parameter defines weights in a two-component mixture distribution. π_1 is interpreted as the prior probability of a genetic variant to have a non-zero effect. $N(\mu, \sigma^2)$ denotes the Gaussian distribution with mean μ and variance σ^2 , and δ_0 indicates a distribution with probability mass at 0 (the Dirac delta function). We will also let $N(x|\mu, \sigma^2) = \frac{1}{\sigma\sqrt{2\pi}} \exp(-\frac{(x-\mu)^2}{2\sigma^2})$ denote the probability density of a normal distribution at point x .

The parameter σ_i^2 defines the variance of effect sizes, with each variant having its own σ_i^2 value reflecting our prior information. The baseline and full GSA-MiXeR models parametrizes σ_i^2 as follows:

$$\begin{aligned} \sigma_{base,i}^2 &= \left(\sigma_{A,0}^2 + \sum_{p=1}^{N_a} [i \in A_p] \sigma_{A,p}^2 \right) \left(\sigma_{G,0}^2 + [i \in G] \sigma_G^2 \right) H_i^S L_i^\ell, \\ \sigma_{full,i}^2 &= \left(\sigma_{A,0}^2 + \sum_{p=1}^{N_a} [i \in A_p] \sigma_{A,p}^2 \right) \left(\sigma_{G,0}^2 + \sum_{q=1}^{N_g} [i \in G_q] \sigma_{G,q}^2 \right) H_i^S L_i^\ell. \end{aligned} \quad (1)$$

Here, the $H_i = 2f_i(1 - f_i)$ term denotes heterozygosity of the i -th variant, such that H_i^S term models allele frequency dependent architectures, with the S parameter controlling the effect size distribution with regards to allele frequency. Similarly, the L_i^ℓ term allows modeling linkage disequilibrium (LD) dependent architectures, where L_i denotes the total LD score of i -th variant, and ℓ denotes the parameter controlling the effect size distribution with regards to LD score. Each of the other two multiplicative factors in Eq. (1) control differential enrichment across genomic annotations and

across genes. The index p runs across annotation categories $\{A_1, A_2, \dots, A_{N_a}\}$, while the parameter $\sigma_{A,p}^2$ represents the contribution of the p -th annotation category to the variance of i -th genetic variant, given that the i -th variant belongs to the p -th category, as specified in Eq. (1) via the indicator variable $[i \in A_p]$, using square brackets notation to transform a logical statement from true or false into 1 and 0, respectively. If genetic variant i belongs to multiple annotation categories, the variances parameters of those annotations will be added together in an additive manner.

Similarly, in the full model, index q runs across genes $\{G_1, G_2, \dots, G_{N_g}\}$, while the parameter $\sigma_{G,q}^2$ represents the contribution of q -th gene. In the baseline model SNPs from all genes are forced to have the same effect size variance parameter σ_G^2 . The parameters $\Sigma_{A,0}^2$ and $\Sigma_{G,0}^2$ allow for non-zero variance σ_i^2 for genetic variants that do not belong to any functional category or gene. In order to simplify the notation in the rest of this Supplementary Note we introduce a fake annotation category A_0 and a “gene” G_0 which both contain all SNPs. We also note that $\sigma_{base,i}^2$ model can be described by $\sigma_{full,i}^2$ model assuming $N_g = 1$, allowing us to derive all formulas just for $\sigma_{full,i}^2$. We’ll use σ_i^2 notation without specifying *base* or *full* subscripts to highlight the fact that formulas derived below are applicable both the base as well as to the full models.

On a technical note, GSA-MiXeR implementation allows G_q to iterate over gene-sets rather than over individual genes. The software also supports non-additive interaction of overlapping annotations or gene-sets, replacing the additive model:

$$\sum_{p=0}^{N_a} [i \in A_p] \sigma_{A,p}^2 \quad \text{and} \quad \sum_{q=0}^{N_g} [i \in G_q] \sigma_{G,q}^2,$$

with a “smooth-max” model defined by:

$$\left(\sum_{p=0}^{N_a} [i \in A_p] \sigma_{A,p}^{2p_a} \right)^{1/p_a} \quad \text{and} \quad \left(\sum_{q=0}^{N_g} [i \in G_q] \sigma_{G,q}^{2p_g} \right)^{1/p_g},$$

where the parameters p_a and p_g controls the “smooth-max” behavior for overlapping annotations and gene-sets, respectively. Note that the p_a and p_g parameters of the GSA-MiXeR are unrelated to the p notation used here to index annotation categories in the above formulas. By default, GSA-MiXeR implementation will use an additive model across overlapping annotations ($p_a = 1$) and across gene-sets ($p_g = 1$). Setting these parameters to e.g. $p_a = 5$ will closely resemble a model where only a single annotation with the largest variance parameter σ_a^2 (the largest among all annotations containing variant i) will contribute to σ_i^2 . Equivalently, setting $p_g = 5$ will trigger similar logic for overlapping gene-sets.

Log-likelihood computation (“full” z-score model)

To infer parameters of the GSA-MiXeR model we use z-scores (z_j) from GWAS summary statistics, where the index $j = 1, \dots, M$ runs over GWAS tag SNPs (imputed or genotyped). Note that the set of GWAS tag SNPs is not necessarily the same as the

set of genetic variants used in modeling additive genetic effects β_i , with $i = 1, \dots, \bar{M}$. In the GSA-MiXeR implementation, the set of genetic variants is formed by SNPs of the Haplotype Reference Consortia (HRC) reference panel, while a subset of HRC SNPs that are also present in GWAS summary statistics is used as a set of tag SNPs. Further details about QC procedures applied to HRC and GWAS variants for filtering low-quality SNPs are described in the Online Methods section of the manuscript. The following equations related additive effects of allele substitution β_i to z -scores from GWAS summary statistics.

Let $\hat{\beta}'_j$ be GWAS estimate of the marginal effect size for j -th tag SNP, assessed via univariate linear regression, and z_j be the corresponding z -score, $z_j = \hat{\beta}'_j / \hat{se}(\beta'_j)$. Then

$$\begin{aligned} z_j &= \delta_j + \epsilon_j, \\ \delta_j &= \sum_{i=1}^{\bar{M}} a_{ij} \beta_i, \text{ where } a_{ij} = \sqrt{N_j H_i} r_{ij}, \\ \epsilon_j &\sim \mathcal{N}(0, \sigma_0^2), \end{aligned} \quad (2)$$

where N_j is the number of subjects with non-missing genotype information on j -th variant; $H_i = 2f_i(1 - f_i)$ is the heterozygosity of i -th variant; $r_{ij} = \text{corr}(\mathbf{v}_i, \mathbf{v}_j)$ is an LD allele count correlation between genotype vectors \mathbf{v}_i , and \mathbf{v}_j (two column-vectors running across individuals, containing dosages g_i and g_j , respectively), parameter σ_0^2 accounts for non-polygenic inflation in GWAS z -scores, and ϵ_j denotes a normally distributed residual.

In the absence of covariates, the least square estimate $\hat{\beta}'_j$ can be expressed as

$$\hat{\beta}'_j = \frac{\mathbf{v}_j^T \mathbf{y}}{\mathbf{v}_j^T \mathbf{v}_j} = \beta_j + \sum_{i \neq j} \hat{\xi}_{ij} \beta_i + \frac{\mathbf{v}_j^T \mathbf{e}}{\mathbf{v}_j^T \mathbf{v}_j} = \sum_i \sqrt{\frac{H_i}{H_j}} r_{ij} \beta_i + \frac{\epsilon_j}{\sqrt{H_j N_j}},$$

where $\hat{\xi}_{ij} = \mathbf{v}_i^T \mathbf{v}_j / \mathbf{v}_j^T \mathbf{v}_j = \hat{\zeta}_{ij} / \hat{\zeta}_{jj}$, with $\hat{\zeta}_{ij} = \mathbf{v}_i^T \mathbf{v}_j / N$ being an estimate of the covariance between i -th and j -th variants:

$$\hat{\zeta}_{ij} \simeq \sqrt{2f_i(1 - f_i)} \sqrt{2f_j(1 - f_j)} r_{ij}.$$

Here, the symbol “ \simeq ” denotes asymptotic equality as $n \rightarrow \infty$. Then using $\hat{se}(\beta'_j) = 1 / \sqrt{H_j N_j}$ result in Eq. (2).

Let $\theta = \{\pi_1, \sigma_i^2, \sigma_0^2\}$ be the vector of parameters of the GSA-MiXeR model, where we simplify notation allowing each SNP to have its own σ_i^2 (but as described above, σ_i^2 is, in turn, parametrized as in Eq. (1)). We now introduce the latent variables $u_i \in \{0, 1\}$ given by a Bernoulli distribution, $p(u_i) = \text{Bern}(u_i | \pi_1)$, so that the full probabilistic

model can be written as follows:

$$\begin{aligned}
p(z_j, \vec{\beta}, \vec{u}|\theta) &= p(z_j|\vec{\beta}, \theta) \cdot p(\vec{\beta}|\vec{u}, \theta) \cdot p(\vec{u}|\theta) , \\
p(z_j|\beta_1, \dots, \beta_M, \theta) &= N\left(z_j \middle| \sum_{i=1}^M a_{ij}\beta_i, \sigma_0^2\right) , \\
p(\beta_i|u_i = 0, \theta) &= N(\beta_i|0, 0) , \quad p(\beta_i|u_i = 1, \theta) = N(\beta_i|0, \sigma_i^2) , \\
p(u_i|\theta) &= \text{Bern}(u_i|\pi_1) .
\end{aligned}$$

A tricky part here is that z_j may depend on multiple β_i . After observing $\vec{z} = (z_1, \dots, z_M)^T$, we are aiming to do inference on θ by the maximum likelihood:

$$p(\vec{z}|\theta) = \prod_j \int_u \int_{\beta} p(z_j, \vec{\beta}, \vec{u}, \theta) du d\beta \rightarrow \max_{\theta}$$

In GSA-MiXeR, we approximate the above integral by drawing $K = 20,000$ samples from $p(u_i)$ for each latent variable u_i . For j -th variant and k -th sampling iteration, let U_{jk} be the set of variants with $u_i = 1$. For each realization of latent variables the distribution over $p(z_j|U_{jk}, \theta)$ became normal zero-mean distribution with a simple analytical formula for its variance:

$$\begin{aligned}
p(z_j|U_{jk}, \theta) &= N(z_j|0, \Sigma_{jk}^2) , \\
\Sigma_{jk}^2 &= \sigma_0^2 + \sum_{i \in U_{jk}} a_{ij}\sigma_i^2 .
\end{aligned}$$

We would like to point out that in practice it is impossible to store all elements of the a_{ij} matrix ($a_{ij} = \sqrt{N_j H_i} r_{ij}$) due to its size. Nevertheless, most of its elements are close to zero, and in GSA-MiXeR we use a sparse matrix (Compressed Sparse Row (CSR) format with delta-encoding and small integer compression) to store all a_{ij} with $r_{ij}^2 \geq r_{min}^2$, by default $r_{min}^2 = 0.01$, considering all pairs of variants within each chromosome regardless of the distance between them, but neglecting potential correlations between different chromosomes. However, the truncated parts of the LD structure (with $r_{min}^2 < 0.01$) may result in slightly inflated σ_0^2 parameter estimates. To reduce this effect, GSA-MiXeR computes partial LD scores $\tilde{L}_j = \sum_{i: r_{ij}^2 < r_{min}^2} a_{ij}^2$ and allow them to contribute to Σ_{jk}^2 under the assumptions of an infinitesimal model with a new variance parameter σ_{0L}^2 to be estimated from the data:

$$\Sigma_{jk}^2 = \sigma_0^2 + \tilde{L}_j \sigma_{0L}^2 + \sum_{i \in U_{jk}} a_{ij}\sigma_i^2 .$$

To clarify how this works, let's consider an infinitesimal model with $\pi_1 = 1$ (all additive genetic effects have non-zero variance) and $\sigma_i^2 = \sigma_{\beta}^2$ (equal variance across all genetic variants). Under these assumptions we can use the above formulas with $u_i = 1$ across all variants to derive $p(z_j|\theta) = N(z_j|0, \sigma_0^2 + \sum_i a_{ij}^2 \sigma_{\beta}^2)$. In this formula $L_j = \sum_i a_{ij}^2 = \sum_i N_j H_i r_{ij}^2$ plays a role of LD score, with a linear relationship between $E(z^2)$ and L_j under the assumptions of an infinitesimal model. In GSA-MiXeR, partial LD scores \tilde{L}_j are, by default, computed across variants with $0.0001 \leq r_{ij}^2 < 0.01$, and the user

has the option to constraint σ_{0L}^2 to 0, or let GSA MiXeR fit σ_{0L}^2 parameter from the data. By default, σ_{0L}^2 is set to zero, and this setting was used throughout all analyses in this work.

The final expression for log-likelihood in GSA-MiXeR is as follows:

$$\log L = \sum_j w_j \log p_j = \sum_j w_j \log \left(\frac{1}{K} \sum_k q(z_j; 0, \sigma_0^2 + \tilde{L}_j \sigma_{0L}^2 + \sum_{i \in U_{jk}} a_{ij} \sigma_i^2) \right), \quad (3)$$

where weights w_j are induced by random-pruning technique to avoid over-counting contribution from large LD blocks, and $q(z; 0, s^2) = \phi(z; 0, s^2) = \frac{1}{\sqrt{2\pi s}} e^{-z^2/2s^2}$ stands for the probability density function of centered normal distribution, except for z-scores that are very large. For large z-scores that exceed certain threshold $|z_j| \geq z_{max}$, the log-likelihood is computed based on right-censoring, i.e., with $q(z_j; 0, s^2) = 2\Phi(-z_{max}; 0, s^2) = \text{erfc}\left(\frac{z_{max}}{\sqrt{2}s}\right)$. A typical value for z_{max} is 5.45, which corresponds to conventional genome-wide significance threshold $\alpha = 5 \times 10^{-8}$.

Log-likelihood gradients

To maximize log-likelihood with regards to parameters θ , GSA-MiXeR employs the Adam algorithm, a stochastic gradient-based optimization, which requires a gradient of the log-likelihood with regard to all parameters. By inspecting Eq. (3) we observe that it is trivial to compute gradients with regards to σ_0^2 , σ_{0L}^2 , and σ_i^2 :

$$\begin{aligned} \frac{\partial \log L}{\partial \sigma_i^2} &= \sum_j \frac{w_j}{K p_j} \sum_{k: i \in U_{jk}} q'_{jk} a_{ij}^2, \\ \frac{\partial \log L}{\partial \sigma_0^2} &= \sum_j \frac{w_j}{K p_j} \sum_k q'_{jk}, \\ \frac{\partial \log L}{\partial \sigma_{0L}^2} &= \sum_j \frac{w_j \tilde{L}_j}{K p_j} \sum_k q'_{jk}, \end{aligned} \quad (4)$$

where

$$\begin{aligned} q_{jk} &= q(z_j; 0, s^2), \quad \text{with} \quad s^2 = \sigma_0^2 + \tilde{L}_j \sigma_{0L}^2 + \sum_{i \in U_{jk}} a_{ij} \sigma_i^2, \\ q'_{jk} &= \frac{\partial \phi(z_j; 0, s^2)}{\partial s^2} = \frac{z^2 - s^2}{2s^4} q_{jk} \quad \text{when} \quad |z_j| < z_{max}, \quad \text{otherwise} \\ q'_{jk} &= \frac{\partial 2\Phi(-z_{max}; 0, s^2)}{\partial s^2} = \frac{z_{max} e^{-\frac{z_{max}^2}{2s^2}}}{\sqrt{2\pi} s^3} = \frac{z_{max}}{s^2} \phi(z_{max}; 0, s^2). \end{aligned}$$

Generally, s^2 in the above formulas should appear as s_{jk}^2 , i.e., indexed by j and k ; the indices that were omitted in the formulas above in favor of less heavy notation. When implemented in GSA-MiXeR software, these formulas result in a numeric vector with length $M + 2$, where the two last elements correspond to the σ_0^2 and σ_{0L}^2 gradients, and the remaining elements corresponding to M gradients, i.e., one for each genetic

variant, with M typically being around 10^7 . Interestingly, the joint computation of all these derivatives takes approximately the same time as computing the log-likelihood function, because for each σ_i^2 the gradient only depends on a smaller set of GWAS tag SNPs that are in LD with i . Another good analogy of this is the backpropagation of errors in neural networks, which also takes a similar time as computing a forward pass over the neural network.

To conclude the computation of log-likelihood gradients we need to consider all parameters of the GSA-MiXeR model that needs to be optimized. These parameters are as follows:

- π_1 - the polygenicity parameter;
- σ_i^2 - the variance parameter of each SNP, which in turn depend on S and ℓ (parameters of effect size distribution with regards to allele frequency and LD), $\sigma_{A,p}^2$ (a set of variance parameters, one for each annotation category) and $\sigma_{G,q}^2$ (a set of variance parameters, one for each gene);
- σ_0^2 - inflation parameter;
- σ_{0L}^2 - inflation capturing the truncated parts of the LD matrix.

To avoid having boundaries on these parameters during optimization, we further parametrize π_1 using the logistic function, $\pi_1(x) = \frac{e^x}{1+e^x}$, with x here being the actual parameter used during optimization; all non-negative variance parameters are further parametrized with an exponential function, $\sigma^2(A, p) = e^{x_p}$ and $\sigma^2(G, q) = e^{y_q}$; parameters S and ℓ are unbounded, and thus are used directly during optimization.

Now, we further re-parametrize σ_i^2 as follows, to reduce collinearity among parameters:

$$\sigma_i^2 = \frac{\sigma_\beta^2}{\pi_1} \left(\sum_{p=0}^{N_a} [i \in A_p] e^{p_a x_p} \right)^{\frac{1}{p_a}} \left(\sum_{q=0}^{N_g} [i \in G_q] e^{p_g y_q} \right)^{\frac{1}{p_g}} \frac{H_i^S}{\frac{1}{M} \sum_t H_t^S} \frac{L_i^\ell}{\frac{1}{M} \sum_t L_t^\ell}, \quad (5)$$

where $t = 1, \dots, \bar{M}$ runs across all SNPs. The above formula differs from Eq. (1) only by a factor $\frac{\sigma_\beta^2}{\pi_1} \frac{1}{\frac{1}{M} \sum_t H_t^S} \frac{1}{\frac{1}{M} \sum_t L_t^\ell}$ that is the same for all SNPs, thus it does not change the relative effect size distribution across genetic variants. Here we introduced a global σ_β^2 parameter which allows for simultaneously adjusting all σ_i^2 up or down, which plays a role if one fits the GSA-MiXeR model with constrained variance parameters for annotation categories and genes. Further, we divided all σ_i^2 by the polygenicity parameter π_1 , making sure that the polygenicity parameter itself does not affect heritability estimate $h^2 = \sum_i \pi_i H_i \sigma_i^2$. Finally, we normalize the formula by mean H_i^S over genetic variants, and also by mean L_i^ℓ over genetic variants, so that changes in S and ℓ parameters also have a minimal effect on the heritability estimate. The idea behind the parametrization of Eq. (5) is that the heritability estimate $h^2 = \sum_i \pi_i H_i \sigma_i^2$ has a substantial impact on log-likelihood, and fine-tuning of other parameters that control intricate aspects of the genetic architecture is more robust when total heritability is constrained to a given value.

Now everything is set to finalize gradient computation.

The π_1 parameter is treated specially, in a sense that $\frac{\partial \log L}{\partial \pi_1}$ is estimated numerically using finite difference

$$\frac{\log L(x + \Delta x) - \log L(x - \Delta x)}{2\Delta x},$$

where step Δx changes adaptively depending on the iteration, and is set to the value used in the Adam algorithm.

We already derived gradients for σ_0^2 and σ_{0L}^2 , except for the parametrization $\sigma_0^2(x)$ which uses an exponential function, $\sigma_0^2(x) = e^x$, so we need to use corresponding gradient with regards to x , i.e., $\frac{\partial \log L}{\partial x} = \frac{\partial \log L}{\partial \sigma_0^2} \times \frac{\partial \sigma_0^2(x)}{\partial x} = \sigma_0^2 \frac{\partial \log L}{\partial \sigma_0^2}$, and similarly for σ_{0L}^2 .

All of the remaining parameters ($S, \ell, \sigma_\beta^2(x), \sigma_{A,p}^2(x_p), \sigma_{G,q}^2(y_q)$) enter into the log-likelihood only via σ_i^2 , thus we will now derive $\frac{\partial \sigma_i^2}{\partial S}, \frac{\partial \sigma_i^2}{\partial \ell}, \frac{\partial \sigma_i^2}{\partial x}, \frac{\partial \sigma_i^2}{\partial x_p}, \frac{\partial \sigma_i^2}{\partial y_q}$, and then calculate the final gradient as follows:

$$\frac{\partial \log L}{\partial S} = \sum_i \frac{\partial \log L}{\partial \sigma_i^2} \frac{\partial \sigma_i^2}{\partial S},$$

and similarly for all other parameters.

Starting with $\frac{\partial \log L}{\partial S}$ and $\frac{\partial \log L}{\partial \ell}$, let us introduce shorthand notations $T(S) = \sum_t H_t^S / \bar{M}$ and $T(\ell) = \sum_t L_t^\ell / \bar{M}$. Then

$$\left(\frac{H_i^S}{T(S)} \right)' = \frac{\frac{\partial H_i^S}{\partial S} T(S) - H_i^S T'(S)}{T^2(S)} = \frac{H_i^S}{T(S)} \frac{(\log H_i) T(S) - (\sum_t (\log H_t) H_t^S / M)}{T(S)}.$$

Hence

$$\frac{\partial \sigma_i^2}{\partial S} = \sigma_i^2 \frac{T(S) \log H_i - (\sum_t (\log H_t) H_t^S / \bar{M})}{T(S)},$$

and similarly

$$\frac{\partial \sigma_i^2}{\partial \ell} = \sigma_i^2 \frac{T(\ell) \log L_i - (\sum_t (\log L_t) L_t^\ell / \bar{M})}{T(\ell)}.$$

Note that both $T(S), T(\ell)$ as well as $\sum_t (\log H_t) H_t^S$ and $\sum_t (\log L_t) L_t^\ell$ are independent of i , thus computation of these derivatives takes linear time with regards to the number of variants M .

Turning to $\sigma_{A,p}^2$ and $\sigma_{G,q}^2$, which are in turn parameterized by exponential functions $\sigma_{A,p}^2(x_p) = e^{x_p}$ and $\sigma_{G,q}^2(y_q) = e^{y_q}$, let us first consider a ‘‘smooth-max’’ function $F(x_1, \dots, x_N) = \left(\sum_{u=1}^N e^{px_u} \right)^{\frac{1}{p}}$ and explore the derivative $\frac{\partial F}{\partial x_t}$:

$$\frac{\partial F(x_1, \dots, x_N)}{\partial x_t} = \frac{1}{p} \left(\sum_u e^{px_u} \right)^{\frac{1}{p}-1} p e^{px_t} = F(x_1, \dots, x_N)^{1-p} e^{px_t} = F(x_1, \dots, x_N) \frac{e^{px_t}}{\sum_u e^{px_u}}.$$

As such,

$$\frac{\partial \sigma_i^2}{\partial x_p} = \sigma_i^2 \frac{[i \in A_p] e^{p_a x_p}}{\sum_u [i \in A_u] e^{p_a x_u}} = \sigma_i^2 \frac{[i \in A_p] \sigma_{A,p}^{2p}}{\sum_u [i \in A_u] \sigma_{A,u}^{2p_a}}.$$

In matrix form, $\frac{\partial \sigma_i^2}{x_p}$ follows the same sparsity structure as $[i \in A_p]$ matrix with \bar{M} rows (one row per SNP) and N_a columns (one column per annotation), with each row of this matrix being multiplied by $\sigma_i^2 / \sum_u [i \in A_u] \sigma_{A,u}^{2p_a}$ value (note this value only depends on i , but not on annotation p), and each column is multiplied by $\sigma_{A,p}^{2p_a}$ (a value that only depends on annotation p , but not on i). Such row-wise and column-wise multiplications can be efficiently implemented using matrix-matrix products with a diagonal matrix. Also, note that the “smooth-max” function, being also a $\|x\|_p$ p-norm, scales linearly with regard to the scale of its argument, so we are free to re-scale σ_u^2 by dividing it by its mean to ensure numeric stability even with single precision float-point numbers.

Similarly to $\frac{\partial \sigma_i^2}{x_p}$, for the genes we can derive that

$$\frac{\partial \sigma_i^2}{\partial y_q} = \sigma_i^2 \frac{[i \in G_q] \sigma_{G,q}^{2p}}{\sum_u [i \in G_u] \sigma_{G,u}^{2p_g}}.$$

And finally, for the σ_β^2 that is also parametrized by an exponential function $\sigma_\beta^2(x) = e^x$, we have $\frac{\partial \sigma_i^2}{\partial x} = \sigma_i^2$. This concludes all pieces needed for efficient gradient computation of the log-likelihood function with regard to the parameters of the GSA-MiXeR model.

Hessian matrix of the log-likelihood function

From equations Eq. (1) (heritability model) and Eq. (3) (log-likelihood function) one can derive formulas for computing the Hessian matrix of the log-likelihood function with respect to all $\sigma_{G,q}^2$ parameters ($q = 1, \dots, N_g$), i.e. the $\left\{ \frac{\partial^2 \log L}{\partial \sigma_{G,q_1}^2 \partial \sigma_{G,q_2}^2} \right\}$ matrix. The formulas for $\frac{\partial^2 \log L}{\partial \sigma_{A,p_1}^2 \partial \sigma_{A,p_2}^2}$, i.e. the Hessian matrix with respect to $\sigma_{A,p}^2$ parameters, are largely equivalent, as $\sigma_{A,p}^2$ and $\sigma_{G,q}^2$ in Eq. (1) appear a similar way. Below we show how under relevant conditions the GSA-MiXeR log-likelihood function can be re-written as

$$\log L = \sum_j w_j \log q(z_j; 0, B_j^2), \text{ where } B_j^2 = \sigma_0^2 + \sum_{q=0}^{N_g} v_{jq} \sigma_{G,q}^2, \quad (6)$$

and terms v_{jq} are defined as follows: $v_{jq} = \sum_{i=1}^{\bar{M}} [i \in G_q] a_{ij} \left(\sum_{p=0}^{N_a} [i \in A_p] \sigma_{A,p}^2 \right) H_i^S L_i^\ell$. The v_{jq} elements do not depend on the $\sigma_{G,q}^2$ parameters, thus after differentiation one obtains the following expression for the elements of the Hessian matrix:

$$\frac{\partial^2 \log L}{\partial \sigma_{G,q_1}^2 \partial \sigma_{G,q_2}^2} = \sum_j w_j \frac{v_{jq_1} v_{jq_2} (B_j^2 - 2z_j^2)}{2B_j^6} \quad (7)$$

Eq. (7) is valid both for the off-diagonal ($q_1 \neq q_2$) and the diagonal ($q_1 = q_2$) elements.

The matrix $V = \{v_{jq}\}$ can be computed efficiently as a matrix-matrix multiplication of two sparse matrices: matrix $\{a_{ij}\}$ which has same sparsity structure as the LD matrix, and $\{[i \in G_q] S_i\}$ matrix annotating SNPs to genes, which is highly sparse each gene contains only a small number of SNPs. The term $S_i = \left(\sum_{p=0}^{N_a} [i \in A_p] \sigma_{A,p}^2 \right) H_i^S L_i^\ell$

that is part of the $[i \in G_q]S_i$ expression indicates that all elements in i -th row of the $\{[i \in G_q]\}$ matrix need to be multiplied by S_i - an operation which can be achieved as matrix-matrix multiplication of a diagonal matrix made of S_i elements (i.e. $diag(S_i)$), and the sparse matrix $\{[i \in G_q]\}$. Similarly, the Hessian matrix defined by Eq. (7) can be computed by matrix-matrix multiplication $V'TV$, where V' is a matrix transpose of V , and $T = \text{diag}(w_j \frac{B_j^2 - 2z_j^2}{2B_j^6})$ is a diagonal matrix.

The above computations did not account for covariance in the errors of $\sigma_{G,q}^2$ and $\sigma_{A,p}^2$ estimates, i.e. we ignored the $\frac{\partial^2 \log L}{\partial \sigma_{G,q}^2 \partial \sigma_{A,p}^2}$ term of the Hessian matrix. Additionally, the formulas were derived specifically for the base and the full GSA-MiXeR models as configured in our main and exploratory analyses, applying $\pi_1 = 1$ assumption (so that the log-likelihood expression was accurate already with a single sampling iteration, $K = 1$), $\sigma_{0L}^2 = 0$ (for the parameter which captures inflation due to the truncation of the LD matrix), disable “right-censoring” feature (or, equivalently, assume a large enough value of the z_{max} parameter), and use $p_a = 1$ and $p_g = 1$ parameters (additive contribution from overlapping genes and functional annotations, without modeling “smooth-max” model). We also introduced the $S_i = \left(\sum_{p=0}^{N_a} [i \in A_p] \sigma_{A,p}^2 \right) H_i^S L_i^\ell$ term so that the heritability model can be expressed as $\sigma_i^2 = S_i \left(\sum_{q=0}^{N_g} [i \in G_q] \sigma_{G,q}^2 \right)$; subsequently, the log-likelihood function can be written as follows:

$$\log L = \sum_j w_j \log p_j = \sum_j w_j \log q \left(z_j; 0, \sigma_0^2 + \sum_{i=1}^{\bar{M}} \sum_{q=0}^{N_g} [i \in G_q] a_{ij} S_i \sigma_{G,q}^2 \right),$$

where $q(z; 0, s^2) = \phi(z; 0, s^2) = \frac{1}{\sqrt{2\pi s}} e^{-z^2/2s^2}$ stands for the probability density function of centered normal distribution. Final formulas for the Hessian matrix (Eq. (7)) are derived from the above $\log L$ expression by applying standard differentiation rules.

Standard errors exceeding 5 times the respective point estimate were capped at this value, in order to limit the detrimental effect of erroneously large SE estimates of individual genes on the gene-sets. Hessian-based SEs are derived from the Taylor series expansion of the log-likelihood function around the MLE point, thus from a theoretical standpoint they are only valid locally, i.e. when SEs are “small enough”; to this end, capping SEs at no more than 5-times the point estimate as per our empirical heuristic is unlikely to make them worse. Second, hessian-based SEs are only valid in the interior of the parameter space and may fail next to its boundary - which may happen in the case of the GSA-MiXeR model if the σ_g^2 parameter estimate for a particular gene is approaching zero. Our real-data analysis is unlikely to be affected by either of these issues, as we are already filtering genes on positive AIC values, which implies sufficient curvature of the log-likelihood around the MLE point and justify hessian-based SEs estimation.

Gaussian approximation (“fast” z-score model)

In this section we will assume $\beta_i \sim (1 - \pi_i)N(0, 0) + \pi_i N(0, \sigma_i^2)$, allowing for π_i to vary across SNPs, in addition to varying σ_i^2 across SNPs as modeled previously.

Lemma. Raw moments of $E\beta_i^2$ and $E\beta_i^4$ are as follows:

$$\begin{aligned} E\beta_i^2 &= \pi_i\sigma_i^2, \\ E\beta_i^4 &= 3\pi_i\sigma_i^4. \end{aligned} \quad (8)$$

Let X_i be a set of independent random variables, and $Y = \sum_i \pi_i X_i$ be mixture distribution. Then all raw moments EY^n are given by a linear combination $\sum_i \pi_i EX_i^n$. This trivial fact follows directly from the definition of the expectation operator: $EY^n = \int_{-\infty}^{\infty} x^n dF_Y(x) = \int_{-\infty}^{\infty} x^n \sum_i \pi_i dF_{X_i}(x) = \sum_i \pi_i EX_i^n$. ■

Lemma. Let $\delta_j = \sum_i a_{ij}\beta_j$, where $a_{ij} = \sqrt{N_j}\sqrt{H_i}r_{ij}$. Then raw moments of $E\delta_j^2$ and $E\delta_j^4$ are as follows:

$$\begin{aligned} E\delta_j^2 &= \sum_i a_{ij}^2 E\beta_i^2 = \sum_i a_{ij}^2 \pi_i \sigma_i^2, \\ E\delta_j^4 - 3(E\delta_j^2)^2 &= \sum_i a_{ij}^4 \left(E\beta_i^4 - 3(E\beta_i^2)^2 \right) = \sum_i 3a_{ij}^4 \pi_i (1 - \pi_i) \sigma_i^4. \end{aligned} \quad (9)$$

The first equation $E\delta_j^2 = \sum_i a_{ij}^2 E\beta_i^2$ is simply because β_i are independent zero-mean random variables.

Let A_i and B_i be some arbitrary expressions. Then $(\sum_i B_i)^2 = \sum_i B_i^2 + 2\sum_{i<j} B_i B_j$, and $(\sum_i A_i)^4 = \sum_i A_i^4 + 6\sum_{i<j} A_i^2 A_j^2 + \dots$, where omitted terms contain at least one odd power of A_i . Consequently, if A_i are independent zero-mean random variables, then $E[(\sum_i A_i)^4] = E[\sum_i A_i^4 + 6\sum_{i<j} A_i^2 A_j^2] = \sum_i E[A_i^4] + 6\sum_{i<j} E[A_i^2]E[A_j^2]$, where the square brackets in $E[x]$ notation define the argument of the expectancy operator in cases when Ex notation becomes ambiguous. Using the above expression for $(\sum_i B_i)^2$ with $B_i = E[A_i^2]$, we get $2\sum_{i<j} E[A_i^2]E[A_j^2] = (\sum_i E[A_i^2])^2 - \sum_i (E[A_i^2])^2$. Therefore,

$$E[(\sum_i A_i)^4] = \sum_i E[A_i^4] + 3\left((\sum_i E[A_i^2])^2 - \sum_i (E[A_i^2])^2 \right).$$

Replacing $(\sum_i E[A_i^2])$ with $E[(\sum A_i)^2]$, we get

$$E[(\sum_i A_i)^4] - \left(E[(\sum A_i)^2] \right)^2 = \sum_i \left(E[A_i^4] - 3(E[A_i^2])^2 \right).$$

Using expression $A_i = a_{ij}\beta_i$, we get

$$E\delta_j^4 - 3(E\delta_j^2)^2 = \sum_i a_i^4 \left(E\beta_i^4 - 3(E\beta_i^2)^2 \right). \quad \blacksquare$$

Lemma. Let A and B be two numeric values, $\tilde{\delta}_j = p_0 N(0, 0) + p_1 N(0, s^2)$ so that

$$p_0 = \frac{B}{B + 3A^2}, \quad p_1 = \frac{3A^2}{B + 3A^2}, \quad s^2 = \frac{B + 3A^2}{3A}. \quad (10)$$

Then, by trivial computation, $E\tilde{\delta}_j^2 = A$, and $E\tilde{\delta}_j^4 - 3(E\tilde{\delta}_j^2)^2 = B$. ■

Substituting $A_j \equiv E\delta_j^2 = \sum_i a_{ij}^2 \pi_i \sigma_i^2$ and $B_j \equiv E\delta_j^4 - 3(E\delta_j^2)^2 = \sum_i 3a_{ij}^4 \pi_i (1 - \pi_i) \sigma_i^4$ into Eq. (10) yields explicit formulas defining p_{j0} , p_{j1} and s_j^2 for the distribution $\tilde{\delta}_j =$

$p_{0j}N(0,0) + p_{1j}N(0, s_j^2)$ which approximates true distribution for $\delta_j = \sum_i a_{ij}\beta_i$, in a sense that $E\delta_j^2 = E\tilde{\delta}_j^2$ and $E\delta_j^4 = E\tilde{\delta}_j^4$. From these expressions, one can derive explicit formulas for computation of the gradients $\frac{\partial p(z_j)}{\partial \pi_i}$ and $\frac{\partial p(z_j)}{\partial \sigma_i^2}$.

The log-likelihood optimization in GSA-MiXeR utilizes the Adam algorithm defined in (1), with specific details of its application explained in Online Methods section.

Algorithm 1: Adam algorithm for GSA-MiXeR inference

Input: $\alpha_1, \dots, \alpha_N$: Stepsize for each epoch
Input: $\beta_1, \beta_2 \in [0, 1)$: Exponential decay rates for the moment estimates
Input: $f(\theta, X)$: Stochastic objective function with parameters θ on batch X
Input: θ_0 : Initial parameter vector
 $m_0 \leftarrow 0$ (Initialize 1st moment vector)
 $v_0 \leftarrow 0$ (Initialize 2nd moment vector)
 $\leftarrow 0$ (Initialize timestep)
for n **in** $1, \dots, N$ **do**
 for X **in** $shuffle(X_1, \dots, X_{22})$ **do**
 $t \leftarrow t + 1$
 $g_t \leftarrow \nabla_{\theta} f_t(\theta_{t-1}, X)$ (Get gradients w.r.t. stochastic objective at time t)
 $m_t \leftarrow \beta_1 \cdot m_{t-1} + (1 - \beta_1) \cdot g_t$ (Update biased 1st moment estimate)
 $v_t \leftarrow \beta_2 \cdot v_{t-1} + (1 - \beta_2) \cdot g_t^2$ (Update biased 2nd raw moment estimate)
 $\hat{m}_t \leftarrow m_t / (1 - \beta_1^t)$ (Compute bias-corrected 1st moment estimate)
 $\hat{v}_t \leftarrow v_t / (1 - \beta_2^t)$ (Compute bias-corrected 2nd raw moment estimate)
 $\theta_t \rightarrow \theta_{t-1} - \alpha_n \cdot \hat{m}_t / (\sqrt{\hat{v}_t} + \epsilon)$ (Update parameters)
 end
end
Result: θ_t (Resulting parameters)

Simulations with pre-defined levels of fold enrichment

Let G and g be two regions in a genome, and g be a subset of G . For example, G can be the set of all genes, while g be a subset of genes. Let H_G and H_g be the total heterozygosity (i.e. $2p(1-p)$ where p is minor allele frequency) combined across all causal variants in regions G and g , respectively.

Let effect size variance for causal SNPs in $G \setminus g$ (i.e. set difference ‘‘G minus g’’) be σ_G^2 , while effect size variance for SNPs in g be $(\sigma_G^2 + \sigma_g^2)$. Let’s also assume that there are no causal variants outside G . Then, the total heritability of a trait simulated according to the above model is $h^2 = H_G \sigma_G^2 + H_g \sigma_g^2$. Under the null model (no enrichment) we let σ_{null}^2 be the effect size variance for causal variants in G . Then the heritability under the null model is $h^2 = H_G \sigma_{null}^2$.

Heritability within the region g can be expressed as $h^2(g) = H_g(\sigma_g^2 + \sigma_G^2)$ (under full model) or $H^2(g) = H_g \sigma_{null}^2$ (under null model). Therefore, fold enrichment of heritability is expected to be $f(g) = (\sigma_g^2 + \sigma_G^2) / \sigma_{null}^2$.

Using the above equations, and assuming that H_g, H_G, h^2 and $f(g)$ are known param-

eters one can derive that

$$\begin{aligned}\sigma_G^2 &= h^2 \frac{H_G - f(g)H_g}{H_G(H_G - H_g)} \\ \sigma_G^2 + \sigma_g^2 &= h^2 f(g)/H_G,\end{aligned}\tag{11}$$

(under a constraint that $f(g)$ does not exceed H_G/H_g ratio). We will use the above formulas to simulate a trait with pre-defined heritability and fold enrichment in a region g over a wider region G . Note the ratio has the following formula:

$$\frac{\sigma_G^2 + \sigma_g^2}{\sigma_G^2} = f(g) \frac{H_G - H_g}{H_G - f(g)H_g}$$

Finally, $h^2(g) = H_g(\sigma_g^2 + \sigma_G^2) = h^2 f(g)H_g/H_G$. This last formula can be applied also to individual genes within g , which can be written as $\sum_i H_i \beta_i^2$ across causal SNPs. After drawing β_i from normal distribution we can re-scale β_i by a constant factor to achieve the expected $h^2(g)$.

Extended authors list: *Mapping genomic loci implicates genes and synaptic biology in schizophrenia*, Nature, 2022.

Vassily Trubetskiy^{1†}, Antonio F Pardiñas^{2†}, Ting Qi^{3,4}, Georgia Panagiotaropoulou¹, Swapnil Awasthi¹, Tim B Bigdeli^{5,6,7}, Julien Bryois⁸, Chia-Yen Chen^{9,10,11}, Charlotte A Dennison², Lynsey S Hall², Max Lam^{12,13,14}, Kyoko Watanabe¹⁵, Oleksandr Frei^{16,17,18}, Tian Ge^{11,12,19}, Janet C Harwood², Frank Koopmans²⁰, Sigurdur Magnusson²¹, Alexander L Richards², Julia Sidorenko³, Yang Wu³, Jian Zeng³, Jakob Grove^{22,23,24}, Minsoo Kim²⁵, Zhiqiang Li^{26,27}, Georgios Voloudakis²⁸, Wen Zhang^{28,29}, Mark Adams³⁰, Ingrid Agartz^{16,31,32}, Elizabeth G Atkinson^{10,12}, Esben Agerbo^{22,33}, Mariam Al Eissa³⁴, Margot Albus³⁵, Madeline Alexander³⁶, Behrooz Z Alizadeha^{37,38}, Köksal Alptekin^{39,40}, Thomas D Als^{22,23,24}, Farooq Amin⁴¹, Volker Arolt⁴², Manuel Arrojo⁴³, Lavinia Athanasiu^{16,17}, Maria Helena Azevedo⁴⁴, Silviu A Bacanu⁴⁵, Nicholas J Bass³⁴, Martin Begemann⁴⁶, Richard A Belliveau¹², Judit Bene⁴⁷, Beben Benyamin^{48,49,50}, Sarah E Bergen⁸, Giuseppe Blasi⁵¹, Julio Bobes^{52,53,54}, Stefano Bonassi⁵⁵, Alice Braun¹, Rodrigo Affonseca Bressan^{56,57}, Evelyn J Bromet⁵⁸, Richard Bruggeman^{37,59}, Peter F Buckley⁶⁰, Randy L Buckner⁶¹, Jonas Bybjerg-Grauholm^{22,62}, Wiepke Cahn^{63,64}, Murray J Cairns^{65,66,67}, Monica E Calkins⁶⁸, Vaughan J Carr^{69,70,71}, David Castle^{72,73}, Stanley V Catts^{74,75}, Kimberley D Chambert¹², Raymond CK Chan^{76,77}, Boris Chaumette^{78,79}, Wei Cheng⁸⁰, Eric FC Cheung⁸¹, Siow Ann Chong^{13,82}, David Cohen^{83,84,85}, Angèle Consoli^{83,84}, Quirino Cordeiro⁸⁶, Javier Costas⁸⁷, Charles Curtis^{88,89}, Michael Davidson⁹⁰, Kenneth L Davis⁹¹, Lieuwe de Haan^{92,93}, Franziska Degenhardt⁹⁴, Lynn E DeLisi^{19,95}, Ditte Demontis^{22,23,24}, Faith Dickerson⁹⁶, Dimitris Dikeos⁹⁷, Timothy Dinan^{98,99}, Srdjan Djurovic^{100,101}, Jubao Duan^{102,103}, Giuseppe Ducci¹⁰⁴, Frank Dudbridge¹⁰⁵, Johan G Eriksson^{106,107,108}, Lourdes Fañanás^{109,110}, Stephen V Faraone¹¹¹, Alessia Fiorentino³⁴, Andreas Forstner^{94,112}, Josef Frank¹¹³, Nelson B Freimer^{114,115}, Menachem Fromer¹¹⁶, Alessandra Frustaci¹¹⁷, Ary Gadelha^{56,57}, Giulio Genovese¹², Elliot S Gershon¹¹⁸, Marianna Giannitelli^{83,84}, Ina Giegling¹¹⁹, Paola Giusti-Rodríguez¹²⁰, Stephanie Godard¹²¹, Jacqueline I Goldstein¹⁰, Javier González Peñas^{110,122}, Ana González-Pinto^{110,123}, Srihari Gopal¹²⁴, Jacob Gratten^{3,125}, Michael F Green^{126,127}, Tiffany A Greenwood¹²⁸, Olivier Guillin^{129,130,131}, Sinan Gülöksüz^{132,133}, Raquel E Gur⁶⁸, Ruben C Gur⁶⁸, Blanca Gutiérrez¹³⁴, Eric Hahn¹³⁵, Hakon Hakonarson¹³⁶, Vahram Haroutunian^{91,137,138}, Annette M Hartmann¹¹⁹, Carol Harvey^{72,139}, Caroline Hayward¹⁴⁰, Frans A Henskens¹⁴¹, Stefan Herms¹⁴², Per Hoffmann¹⁴², Daniel P Howrigan^{10,143}, Masashi Ikeda¹⁴⁴, Conrad Iyegbe¹⁴⁵, Inge Joa¹⁴⁶, Antonio Julià¹⁴⁷, Anna K Kähler⁸, Tony Kam-Thong¹⁴⁸, Yoichiro Kamatani^{149,150}, Sena Karachanak-Yankova^{151,152}, Oussama Kebir⁷⁸, Matthew C Keller¹⁵³, Brian J Kelly¹⁴¹, Andrey Khrunin¹⁵⁴, Sung-Wan Kim¹⁵⁵, Janis Klovins¹⁵⁶, Nikolay Kondratiev¹⁵⁷, Bettina Konte¹¹⁹, Julia Kraft^{1,158}, Michiaki Kubo¹⁵⁹, Vaidutis Kučinskas¹⁶⁰, Zita Ausrele Kučinskiene¹⁶⁰, Agung Kusumawardhani¹⁶¹, Hana Kuzelova-Ptackova¹⁶², Stefano Landi¹⁶³, Laura C Lazzeroni^{164,165}, Phil H Lee^{12,166}, Sophie E Legge², Douglas S Lehrer¹⁶⁷, Rebecca Lencer⁴², Bernard Lerer¹⁶⁸, Miaoxin Li¹⁶⁹, Jeffrey Lieberman¹⁷⁰, Gregory A Light^{128,171}, Svetlana Limborska¹⁵⁴, Chih-Min Liu^{172,173}, Jouko Lönnqvist^{174,175}, Carmel M Loughland¹⁷⁶, Jan Lubinski¹⁷⁷, Jurjen J Luyckx^{132,178,179,180}, Amy Lynham², Milan Macek Jr¹⁸¹, Andrew Mackinnon^{182,183}, Patrik KE Magnusson⁸, Brion S Maher¹⁸⁴, Wolfgang Maier¹⁸⁵, Dolores Malaspina^{91,186}, Jacques Mallet¹⁸⁷, Stephen R Marder¹⁸⁸, Sara Marsal¹⁴⁷, Alicia R Martin^{10,12,189}, Lourdes Martorell¹⁹⁰, Manuel Mattheisen^{23,191,192,193}, Robert W McCarley^{194,195}, Colm McDonald¹⁹⁶, John J McGrath^{33,197,198}, Helena Medeiros^{199,200}, Sandra Meier^{191,201}, Bela Melegh²⁰²,

Ingrid Melle^{16,17}, Raquelle I Mesholam-Gately^{19,203}, Andres Metspalu²⁰⁴, Patricia T Michie²⁰⁵, Lili Milani²⁰⁴, Vihra Milanova²⁰⁶, Marina Mitjans⁴⁶, Espen Molden^{207,208}, Esther Molina²⁰⁹, María Dolores Molto^{110,210,211}, Valeria Mondelli^{89,212}, Carmen Moreno^{110,122}, Christopher P Morley²¹³, Gerard Muntané^{190,214}, Kieran C Murphy²¹⁵, Inez Myin-Germeys²¹⁶, Igor Nenadić^{217,218}, Gerald Nestadt²¹⁹, Liene Nikitina-Zake¹⁵⁶, Cristiano Noto^{56,57}, Keith H Nuechterlein¹²⁶, Niamh Louise O'Brien³⁴, F Anthony O'Neill²²⁰, Sang-Yun Oh^{221,222}, Ann Olincy²²³, Vanessa Kiyomi Ota^{57,224}, Christos Pantelis^{139,225,226,227}, George N Papadimitriou⁹⁷, Mara Parellada^{110,122}, Tiina Paunio^{228,229}, Renata Pellegrino¹³⁶, Sathish Periyasamy^{197,230}, Diana O Perkins²³¹, Bruno Pfulmann²³², Olli Pietiläinen^{12,233,234}, Jonathan Pimm³⁴, David Porteous²³⁵, John Powell²³⁶, Diego Quattrone^{88,89,237}, Digby Quested^{238,239}, Allen D Radant^{240,241}, Antonio Rampino⁵¹, Mark H Rapaport²⁴², Anna Rautanen¹⁴⁸, Abraham Reichenberg⁹¹, Cheryl Roe²⁴³, Joshua L Roffman²⁴⁴, Julian Roth²⁴⁵, Matthias Rothermundt⁴², Bart PF Rutten¹³², Safaa Saker-Delye²⁴⁶, Veikko Salomaa²⁴⁷, Julio Sanjuan^{110,211,248}, Marcos Leite Santoro^{57,224}, Adam Savitz¹²⁴, Ulrich Schall^{66,249}, Rodney J Scott^{65,250,251}, Larry J Seidman^{19,203}, Sally Isabel Sharp³⁴, Jianxin Shi²⁵², Larry J Siever^{91,253}, Engilbert Sigurdsson^{254,255}, Kang Sim^{256,257,258}, Nora Skarabis¹, Petr Slominsky¹⁵⁴, Hon-Cheong So^{259,260}, Janet L Sobell¹⁹⁹, Erik Söderman³², Helen J Stain^{261,262}, Nils Eiel Steen^{17,263}, Agnes A. Steixner-Kumar⁴⁶, Elisabeth Stögmann²⁶⁴, William S Stone^{265,266}, Richard E Straub²⁶⁷, Fabian Streit¹¹³, Eric Strengman²⁶⁸, T Scott Stroup¹⁷⁰, Mythily Subramaniam^{13,82}, Catherine A Sugar^{126,269}, Jaana Suvisaari²⁴⁷, Dragan M Svrakic²⁷⁰, Neal R Swerdlow¹²⁸, Jin P Szatkiewicz¹²⁰, Thi Minh Tam Ta^{271,272}, Atsushi Takahashi^{132,273}, Chikashi Terao²⁷³, Florence Thibaut^{274,275}, Draga Toncheva^{151,276}, Paul A Tooney^{65,66,67}, Silvia Torretta⁵¹, Sarah Tosato²⁷⁷, Gian Battista Tura²⁷⁸, Bruce I Turetsky⁶⁸, Alp Üçok²⁷⁹, Arne Vaaler^{280,281}, Therese van Amelsvoort^{89,132}, Ruud van Winkel^{132,282}, Juha Veijola^{283,284}, John Waddington²⁸⁵, Henrik Walter²⁸⁶, Anna Waterreus^{287,288}, Bradley T Webb⁴⁵, Mark Weiser²⁸⁹, Nigel M Williams², Stephanie H Witt¹¹³, Brandon K Wormley⁴⁵, Jing Qin Wu²⁹⁰, Zhida Xu²⁹¹, Robert Yolken²⁹², Clement C Zai^{293,294}, Wei Zhou²⁷, Feng Zhu^{295,296}, Fritz Zimprich²⁶⁴, Eşref Cem Atbaşoğlu^{186,297}, Muhammad Ayub²⁹⁸, Christian Benner²³⁴, Alessandro Bertolino⁵¹, Donald W Black²⁹⁹, Nicholas J Bray², Jerome Breen⁸⁸, Nancy G Buccola³⁰⁰, William F Byerley³⁰¹, Wei J Chen^{302,303}, C Robert Cloninger²⁷⁰, Benedicto Crespo-Facorro^{304,305}, Gary Donohoe¹⁹⁶, Robert Freedman²²³, Cherrie Galletly^{306,307,308}, Michael J Gandal²⁵, Massimo Gennarelli^{309,310}, David M Hougaard^{22,62}, Hai-Gwo Hwu^{173,311}, Assen V Jablensky²⁸⁸, Steven A McCarroll¹², Jennifer L Moran^{12,244}, Ole Mors^{22,312}, Preben B Mortensen^{22,33}, Bertram Müller-Myhsok^{313,314,315}, Amanda L Neil³¹⁶, Merete Nordentoft^{22,317}, Michele T Pato^{318,319}, Tracey L Petryshen¹⁶⁶, Matti Pirinen^{234,320,321}, Ann E Pulver²¹⁹, Thomas G Schulze^{193,322,323,324}, Jeremy M Silverman^{91,253}, Jordan W Smoller^{12,166}, Eli A Stahl^{116,325,326}, Debby W Tsuang^{240,241}, Elisabet Vilella¹⁹⁰, Shi-Heng Wang³²⁷, Shuhua Xu^{328,329,330}, Indonesia Schizophrenia Consortium*, PsychENCODE*, Psychosis Endophenotypes International Consortium*, The SynGO Consortium*, Rolf Adolfsson³³¹, Celso Arango^{110,122}, Bernhard T Baune^{42,226,227}, Sintia Iole Belangero^{57,224}, Anders D Børglum^{22,23,24}, David Braff^{128,171}, Elvira Bramon³³², Joseph D Buxbaum⁹¹, Dominique Campion^{129,130}, Jorge A Cervilla³³³, Sven Cichon^{334,335,336}, David A Collier³³⁷, Aiden Corvin³³⁸, Marta Di Forti^{88,89,237}, Enrico Domenici³⁴¹, Hannelore Ehrenreich⁴⁶, Valentina Escott-Price^{342,343}, Tõnu Esko^{204,325}, Ayman H Fanous^{7,344,345}, Anna Gareeva^{346,347}, Micha Gawlik²⁴⁵, Pablo V Gejman^{102,103}, Michael Gill³³⁸, Stephen J Glatt³⁴⁸, Vera Golimbet¹⁵⁷, Kyung Sue Hong³⁴⁹, Christina M Hultman⁸, Steven E Hyman^{12,233}, Nakao Iwata¹⁴⁴, Erik G Jönsson^{32,263}, René S Kahn^{63,91}, James L Kennedy^{293,294}, Elza

Khusnutdinova^{347,350}, George Kirov², James A Knowles^{351,352}, Marie-Odile Krebs⁷⁸, Claudine Laurent-Levinson^{83,84}, Jimmy Lee^{353,354}, Todd Lencz^{14,355,356}, Douglas F Levinson¹⁶⁴, Qingqin S Li¹²⁴, Jianjun Liu^{357,358}, Anil K Malhotra^{14,355,356}, Dheeraj Malhotra³⁵⁹, Andrew McIntosh³⁰, Andrew McQuillin³⁴, Paulo R Menezes³⁶⁰, Vera A Morgan^{287,288}, Derek W Morris¹⁹⁶, Bryan J Mowry^{197,230}, Robin M Murray^{89,361}, Vishwajit Nimgaonkar³⁶², Markus M Nöthen⁹⁴, Roel A Ophoff^{114,363,364}, Sara A Paciga³⁶⁵, Aarno Palotie^{234,366,367}, Carlos N Pato^{318,319}, Shengying Qin^{27,368}, Marcella Rietschel¹¹³, Brien P Riley⁴⁵, Margarita Rivera^{369,370}, Dan Rujescu¹¹⁹, Meram C Saka²⁹⁷, Alan R Sanders^{102,103}, Sibylle G Schwab^{371,372}, Alessandro Serretti³⁷³, Pak C Sham^{374,375,376}, Yongyong Shi^{27,377}, David St Clair³⁷⁸, Hreinn Stefánsson²¹, Kari Stefansson²¹, Ming T Tsuang^{379,380}, Jim van Os^{381,382}, Marquis P Vawter³⁸³, Daniel R Weinberger²⁶⁷, Thomas Werge^{384,385,386,387}, Dieter B Wildenauer³⁸⁸, Xin Yu^{389,390}, Weihua Yue^{389,390,391}, Peter A Holmans², Andrew J Pocklington², Panos Roussos^{28,392}, Evangelos Vassos^{88,89,393}, Matthijs Verhage^{394,395}, Peter M Visscher³, Jian Yang^{3,4,396}, Danielle Posthuma³⁹⁵, Ole A Andreassen^{16,17}, Kenneth S Kendler⁴⁵, Michael J Owen², Naomi R Wray^{3,197}, Mark J Daly^{10,143,234}, Hailiang Huang^{10,12,189}, Benjamin M Neale^{10,12}, Patrick F Sullivan^{8,120,231}, Stephan Ripke^{1,10,367‡}, James TR Walters^{2‡}, Michael C O'Donovan^{2‡}, Schizophrenia Working Group of the Psychiatric Genomics Consortium*

¹Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin, Germany.

²MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychiatry and Clinical Neurosciences, Cardiff University, Cardiff, UK. ³Institute for Molecular Bioscience, University of Queensland, Brisbane QLD, Australia. ⁴School of Life Sciences, Westlake University, Hangzhou Zhejiang, China. ⁵Department of Psychiatry and the Behavioral Sciences, State University of New York, Downstate Medical Center, New York NY, USA. ⁶Institute for Genomic Health, SUNY Downstate Medical Center, New York NY, USA. ⁷Department of Psychiatry, Veterans Affairs New York Harbor Healthcare System, New York NY, USA.

⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁹Biogen, Cambridge MA, USA. ¹⁰Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA USA. ¹¹Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston MA, USA. ¹²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge MA, USA. ¹³Research Division, Institute of Mental Health, Singapore, Republic of Singapore.

¹⁴Division of Psychiatry Research, Zucker Hillside Hospital, Glen Oaks NY, USA. ¹⁵Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 1081 HV, Amsterdam, The Netherlands.

¹⁶NORMENT Centre, Division of Mental Health and Addiction, University of Oslo, Oslo, Norway. ¹⁷Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

¹⁸Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.

¹⁹Department of Psychiatry, Harvard Medical School, Boston MA, USA. ²⁰Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Faculty of Science, Amsterdam Neuroscience, Vrije Universiteit, Amsterdam, The Netherlands.

²¹deCODE Genetics/Amgen Inc., Reykjavik, Iceland. ²²The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark. ²³Department of Biomedicine and Centre for Integrative Sequencing (iSEQ), Aarhus University, Aarhus, Denmark. ²⁴Center for

Genomics and Personalized Medicine, Aarhus, Denmark. ²⁵Department of Psychiatry, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles CA, USA. ²⁶Affiliated Hospital of Qingdao University & Biomedical Sciences Institute, Qingdao University, Qingdao Shi, China. ²⁷Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science, Shanghai Jiao Tong University, Shanghai, China. ²⁸Department of Psychiatry, Pamela Sklar Division of Psychiatric Genomics, Friedman Brain Institute, Department of Genetics and Genomic Science and Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York NY, USA. ²⁹Department of Genetics & Genomic Sciences and Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York NY, USA. ³⁰Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. ³¹Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway. ³²Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden. ³³National Centre for Register-based Research, Aarhus University, Aarhus, Denmark. ³⁴Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London, UK. ³⁵Comedicum Lindwurmhof, Munich, Germany. ³⁶Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont MA, USA. ³⁷University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, University of Groningen, Groningen, The Netherlands. ³⁸Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ³⁹Department of Psychiatry, Dokuz Eylül University School of Medicine, Izmir, Turkey. ⁴⁰Department of Neuroscience, Dokuz Eylül University Graduate School of Health Sciences, Izmir, Turkey. ⁴¹Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta GA, USA. ⁴²Department of Psychiatry, University of Münster, Münster, Germany. ⁴³Servizo de Psiquiatría, Complexo Hospitalario Universitario de Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela Galicia, Spain. ⁴⁴Institute of Medical Psychology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. ⁴⁵Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University, Richmond VA, USA. ⁴⁶Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany. ⁴⁷Department of Medical Genetics, Medical School, University of Pécs, Pécs, Hungary. ⁴⁸Australian Centre for Precision Health, University of South Australia Cancer Research Institute, University of South Australia, Adelaide SA, Australia. ⁴⁹UniSA Allied Health & Human Performance, University of South Australia, Adelaide SA, Australia. ⁵⁰South Australian Health and Medical Research Institute, Adelaide SA, Australia. ⁵¹Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy. ⁵²Área de Psiquiatría-Universidad de Oviedo, Hospital Universitario Central de Asturias (HUCA), Asturias, Spain. ⁵³Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Asturias, Spain. ⁵⁴Centro de Investigación Biomédica en Red de Salud Mental, Oviedo, Asturias, Spain. ⁵⁵Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, and San Raffaele University, Rome, Italy. ⁵⁶Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo SP, Brazil. ⁵⁷Laboratory of Integrative Neuroscience, Universidade Federal de Sao Paulo, Sao Paulo SP, Brazil. ⁵⁸Department of Psychiatry and Behavioural Health, Stony Brook University, Stony Brook NY, USA. ⁵⁹University of Groningen, Department of Clinical and Developmental

Neuropsychology, Groningen, The Netherlands. ⁶⁰School of Medicine, Virginia Commonwealth University, Richmond VA, USA. ⁶¹Department of Psychology, Harvard University, Cambridge MA, USA. ⁶²Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. ⁶³University Medical Center Utrecht, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands. ⁶⁴Altrecht, General Mental Health Care, Utrecht, The Netherlands. ⁶⁵School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan NSW, Australia. ⁶⁶Hunter Medical Research Institute, Newcastle NSW, Australia. ⁶⁷Centre for Brain & Mental Health Research, The University of Newcastle, Callaghan NSW, Australia. ⁶⁸Department of Psychiatry, University of Pennsylvania, Philadelphia PA, USA. ⁶⁹School of Psychiatry, University of New South Wales, Sydney NSW, Australia. ⁷⁰Department of Psychiatry, Monash University, Melbourne, Australia. ⁷¹Neuroscience Research Australia, Sydney, Australia. ⁷²Department of Psychiatry, The University of Melbourne, Parkville VIC, Australia. ⁷³St Vincent's Hospital, 41 Victoria Parade, Fitzroy VIC, Australia. ⁷⁴Brain and Mind Centre, The University of Sydney, Sydney NSW, Australia. ⁷⁵School of Medicine, University of Queensland, Herston QLD, Australia. ⁷⁶Institute of Psychology, Chinese Academy of Science, Beijing, China. ⁷⁷Department of Psychology, University of Chinese Academy of Sciences, Beijing, China. ⁷⁸INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, Université de Paris, GHU Paris Psychiatrie & Neurosciences, Paris, France. ⁷⁹Department of Psychiatry, McGill University, Montreal, Canada. ⁸⁰Department of Computer Science, University of North Carolina, Chapel Hill NC, USA. ⁸¹Castle Peak Hospital, Hong Kong, China. ⁸²Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Republic of Singapore. ⁸³Faculté de Médecine Sorbonne Université, Groupe de Recherche Clinique n°15 - Troubles Psychiatriques et Développement (PSYDEV), Department of Child and Adolescent Psychiatry, Hôpital Universitaire de la Pitié-Salpêtrière, Paris, France. ⁸⁴Centre de Référence des Maladies Rares à Expression Psychiatrique, Department of Child and Adolescent Psychiatry, AP-HP Sorbonne Université, Hôpital Universitaire de la Pitié-Salpêtrière, Paris, France. ⁸⁵Institut des Systèmes Intelligents et de Robotique (ISIR), CNRS UMR7222, Sorbonne Université, Campus Pierre et Marie Curie, Faculté des Sciences et Ingénierie, Paris, France. ⁸⁶Department of Psychiatry, Irmandade da Santa Casa de Misericórdia de São Paulo, Rua Dona Veridiana, São Paulo SP, Brazil. ⁸⁷Instituto de Investigación Sanitaria (IDIS) de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Servizo Galego de Saúde (SERGAS), Santiago de Compostela Galicia, Spain. ⁸⁸Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ⁸⁹National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK. ⁹⁰University of Nicosia Medical School, Nicosia, Cyprus. ⁹¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York NY, USA. ⁹²Department of Psychiatry, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. ⁹³Arkin, Institute for Mental Health, Amsterdam, The Netherlands. ⁹⁴Institute of Human Genetics, University of Bonn, Bonn, Germany. ⁹⁵Cambridge Health Alliance, Cambridge MA, USA. ⁹⁶Sheppard Pratt Health System, Baltimore MD, USA. ⁹⁷First Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece. ⁹⁸Department of Psychiatry and Neurobehavioural Sciences, University College Cork, Cork, Ireland. ⁹⁹APC Microbiome Ireland, University College Cork, Cork, Ireland.

¹⁰⁰NORMENT Centre, Department of Clinical Science, University of Bergen, Bergen, Norway. ¹⁰¹Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. ¹⁰²Center for Psychiatric Genetics, NorthShore University HealthSystem, Evanston IL, USA. ¹⁰³Department of Psychiatry and Behavioral Neurosciences, The University of Chicago, Chicago IL, USA. ¹⁰⁴Department of Mental Health, ASL Rome 1, Rome, Italy. ¹⁰⁵Department of Health Sciences, University of Leicester, Leicester, UK. ¹⁰⁶Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ¹⁰⁷Folkhälsan Research Center, Helsinki, Finland. ¹⁰⁸Department of Obstetrics & Gynecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore. ¹⁰⁹Department of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona, Barcelona, Spain. ¹¹⁰Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain. ¹¹¹Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse NY, USA. ¹¹²Centre for Human Genetics, University of Marburg, Marburg, Germany. ¹¹³Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ¹¹⁴Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles BA, USA. ¹¹⁵Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles CA, USA. ¹¹⁶Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York NY, USA. ¹¹⁷Barnet, Enfield and Haringey Mental Health NHS Trust, St. Ann's Hospital, London, UK. ¹¹⁸Departments of Psychiatry and Human Genetics, University of Chicago, Chicago IL, USA. ¹¹⁹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. ¹²⁰Department of Genetics, University of North Carolina, Chapel Hill NC, USA. ¹²¹Departments of Psychiatry and Human and Molecular Genetics, INSERM, Institut de Myologie, Hôpital de la Pitié-Salpêtrière, Paris, France. ¹²²Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain. ¹²³BIOARABA Health Research Institute. OSI Araba. University Hospital, University of the Basque Country, Vitoria, Spain. ¹²⁴Neuroscience Therapeutic Area, Janssen Research and Development, Titusville NJ, USA. ¹²⁵Mater Research Institute, University of Queensland, Brisbane QLD, Australia. ¹²⁶Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California Los Angeles, Los Angeles CA, USA. ¹²⁷VA Greater Los Angeles Healthcare System, Los Angeles CA, USA. ¹²⁸Department of Psychiatry, University of California San Diego, La Jolla CA, USA. ¹²⁹INSERM, Rouen, France. ¹³⁰Centre Hospitalier du Rouvray, Rouen, France. ¹³¹UFR santé, Université de Rouen Normandie, Rouen, France. ¹³²Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands. ¹³³Department of Psychiatry, Yale School of Medicine, New Haven CT, USA. ¹³⁴Department of Psychiatry, Faculty of Medicine and Biomedical Research Centre (CIBM), University of Granada, Granada, Spain. ¹³⁵Department of Psychiatry, Charité - Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany. ¹³⁶Children's Hospital of Philadelphia, Leonard Madlyn Abramson Research Center, Philadelphia PA, USA. ¹³⁷Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York NY, USA. ¹³⁸Mental Illness Research Clinical and Education Center (MIRECC), JJ Peters VA Medical Center, New York NY, USA. ¹³⁹NorthWestern Mental Health,

Melbourne VIC, Australia. ¹⁴⁰MRC Human Genetics Unit, University of Edinburgh, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK. ¹⁴¹School of Medicine and Public Health, University of Newcastle, Newcastle NSW, Australia. ¹⁴²Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland. ¹⁴³Broad Institute of MIT and Harvard, Cambridge MA, USA. ¹⁴⁴Department of Psychiatry, Fujita Health University School of Medicine, Toyoake Aichi, Japan. ¹⁴⁵Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ¹⁴⁶Regional Centre for Clinical Research in Psychosis, Department of Psychiatry, Stavanger University Hospital, Stavanger, Norway. ¹⁴⁷Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain. ¹⁴⁸Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffman-La Roche Ltd, Basel, Switzerland. ¹⁴⁹Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ¹⁵⁰Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama Kanagawa, Japan. ¹⁵¹Department of Medical Genetics, Medical University, Sofia, Bulgaria. ¹⁵²Department of Genetics, Faculty of Biology, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria. ¹⁵³Institute for Behavioural Genetics, University of Colorado Boulder, Boulder CO, USA. ¹⁵⁴Institute of Molecular Genetics of National Research Centre "Kurchatov Institute", Moscow, Russia. ¹⁵⁵Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea. ¹⁵⁶Latvian Biomedical Research and Study Centre, Riga, Latvia. ¹⁵⁷Mental Health Research Center, Moscow, Russian Federation. ¹⁵⁸Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany. ¹⁵⁹RIKEN Center for Integrative Medical Sciences, Yokohama Kanagawa, Japan. ¹⁶⁰Faculty of Medicine, Vilnius University, Vilnius, Lithuania. ¹⁶¹Psychiatry Department, University of Indonesia - Cipto Mangunkusumo National General Hospital, Jakarta Pusat, DKI Jakarta, Jakarta, Indonesia. ¹⁶²Department of Psychiatry, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic. ¹⁶³Dipartimento di Biologia, Università di Pisa, Pisa, Italy. ¹⁶⁴Departments of Psychiatry and Behavioral Sciences, Stanford University, Stanford CA, USA. ¹⁶⁵Department of Biomedical Data Science, Stanford University, Stanford CA, USA. ¹⁶⁶Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA. ¹⁶⁷Department of Psychiatry, Wright State University, 3640 Colonel Glenn Hwy, Dayton OH, USA. ¹⁶⁸Department of Psychiatry, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. ¹⁶⁹Zhongshan School of Medicine and Key Laboratory of Tropical Diseases Control (SYSU), Sun Yat-sen University, Guangzhou, China. ¹⁷⁰Department of Psychiatry, Columbia University, New York NY, USA. ¹⁷¹VISN 22, Mental Illness Research, Education & Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego CA, USA. ¹⁷²Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan. ¹⁷³Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan. ¹⁷⁴Mental Health Unit, Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland. ¹⁷⁵Department of Psychiatry, University of Helsinki, Helsinki, Finland. ¹⁷⁶Hunter New England Health & University of Newcastle, Newcastle NSW, Australia. ¹⁷⁷Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, Szczecin, Poland. ¹⁷⁸Department of Psychiatry, UMC Utrecht Brain Center, University Medical Centre Utrecht, Utrecht University, Utrecht, The

Netherlands. ¹⁷⁹Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center, Utrecht, Utrecht University, Utrecht, The Netherlands. ¹⁸⁰Second opinion outpatient clinic, GGNet mental health, Warnsveld, The Netherlands. ¹⁸¹Department of Biology and Medical Genetics, 2nd Faculty of Medicine and University Hospital Motol, 150 06 Prague, Czech Republic. ¹⁸²Black Dog Institute, University of new South Wales, Randwick NSW, Australia. ¹⁸³Melbourne School of Population and Global health, University of Melbourne VIC, Australia. ¹⁸⁴Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore MD, USA. ¹⁸⁵Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany . ¹⁸⁶Department of Genetics & Genomics, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York NY, USA. ¹⁸⁷Asfalia Biologics, iPEPS-ICM, Hôpital Universitaire de la Pitié-Salpêtrière, Paris, France. ¹⁸⁸Semel Institute for Neurosciene, University of California, Los Angeles CA, USA. ¹⁸⁹Department of Medicine, Harvard Medical School, Boston MA, USA. ¹⁹⁰Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain. ¹⁹¹Department of Psychiatry, Dalhousie University, Halifax NS, Canada. ¹⁹²Department of Community Health and Epidemiology, Dalhousie University, Halifax Nova Scotia, Canada. ¹⁹³Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany. ¹⁹⁴VA Boston Health Care System, Brockton MA, USA. ¹⁹⁵Deceased. ¹⁹⁶Centre for Neuroimaging, Cognition and Genomics (NICOG), National University of Ireland Galway, Galway, Ireland. ¹⁹⁷Queensland Brain Institute, The University of Queensland, Brisbane QLD, Australia. ¹⁹⁸Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Queensland, Australia. ¹⁹⁹Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles CA, USA. ²⁰⁰College of Medicine, SUNY Downstate Health Sciences University, New York NY, USA. ²⁰¹Department of Biomedicine, Aarhus University, Aarhus, Denmark. ²⁰²Department of Medical Genetics, University of Pécs, Pécs, Hungary. ²⁰³Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston MA, USA. ²⁰⁴Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia. ²⁰⁵School of Psychology, University of Newcastle, Newcastle NSW, Australia. ²⁰⁶First Psychiatric Clinic, Medical University, Sofia, Bulgaria. ²⁰⁷Department of Pharmacy, University of Oslo, Oslo, Norway. ²⁰⁸Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. ²⁰⁹Department of Nursing, Faculty of Health Sciences and Biomedical Research Centre (CIBM), University of Granada, Granada, Spain. ²¹⁰Department of Genetics, Faculty of Biological Sciences, Campus of Burjassot, Universidad de Valencia, Valencia, Spain. ²¹¹Biomedical Research Institute INCLIVA, Valencia, Spain. ²¹²Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK. ²¹³Departments of Public Health and Preventive Medicine, Family Medicine, and Psychiatry and Behavioral Sciences, State University of New York, Upstate Medical University, Syracuse NY, USA. ²¹⁴Institut de Biologia Evolutiva (UPF-CSIC), Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain. ²¹⁵Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. ²¹⁶Department for Neurosciences, Center for Contextual Psychiatry, KU Leuven, Leuven, Belgium. ²¹⁷Cognitive Neuropsychiatry Lab, Department of Psychiatry and Psychotherapy, Philipps Universität Marburg, Marburg, Germany. ²¹⁸Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany. ²¹⁹Department of Psychiatry and

Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore MD, USA.

²²⁰Centre for Public Health, Institute of Clinical Sciences, Queen's University Belfast, Belfast, UK. ²²¹Department of Statistics and Applied Probability, University of California at Santa Barbara, Santa Barbara CA, USA. ²²²Computational Research Division, Lawrence Berkeley National Laboratory, Berkeley CA, USA. ²²³Department of Psychiatry, University of Colorado Denver, Aurora CO, USA. ²²⁴Department of Morphology and Genetics, Universidade Federal de Sao Paulo, Laboratorio de Genetica, Sao Paulo SP, Brazil. ²²⁵Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Melbourne VIC, Australia. ²²⁶The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia. ²²⁷Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Parkville VIC, Australia. ²²⁸Department of Public Health Solutions, Genomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland. ²²⁹Department of Psychiatry and SleepWell Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. ²³⁰Queensland Centre for Mental Health Research, The University of Queensland, Brisbane QLD, Australia. ²³¹Department of Psychiatry, University of North Carolina, Chapel Hill NC, USA. ²³²Clinic of Psychiatry and Psychotherapy, Weißer Hirsch, Dresden, Germany. ²³³Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge MA, USA. ²³⁴Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ²³⁵Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK. ²³⁶Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ²³⁷South London and Maudsley NHS Mental Health Foundation Trust, London, UK. ²³⁸Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK. ²³⁹Department of Psychiatry, University of Oxford, Oxford, UK. ²⁴⁰Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle WA, USA. ²⁴¹VA Puget Sound Health Care System, Seattle WA, USA. ²⁴²Huntsman Mental Health Institute, Department of Psychiatry, University of Utah School of Medicine, Salt Lake City UT, USA. ²⁴³SUNY Upstate Medical University, Syracuse NY, USA. ²⁴⁴Department of Psychiatry, Massachusetts General Hospital, Boston MA, USA. ²⁴⁵Department of Psychiatry, Psychosomatics and Psychotherapy, Julius-Maximilians-Universität Würzburg, Wuerzburg, Germany. ²⁴⁶Généthon, Evry, France. ²⁴⁷THL-Finnish Institute for Health and Welfare, Helsinki, Finland. ²⁴⁸Department of Psychiatry, School of Medicine, University of Valencia, Hospital Clínico Universitario de Valencia, Spain. ²⁴⁹Priority Centre for Brain & Mental Health Research, The University of Newcastle, Mater Hospital, McAuley Centre, Waratah NSW, Australia. ²⁵⁰Division of Molecular Medicine, NSW Health Pathology North, Newcastle, NSW, Australia. ²⁵¹Hunter Medical Research Institute, Newcastle NSW, Australia. ²⁵²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda MD, USA. ²⁵³James J. Peters VA Medical Center, New York NY, USA. ²⁵⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ²⁵⁵Department of Psychiatry, Landspítali University hospital, Reykjavik, Iceland. ²⁵⁶West Region, Institute of Mental Health, Singapore, Singapore. ²⁵⁷Yoo Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ²⁵⁸Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. ²⁵⁹School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China. ²⁶⁰Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, China.

²⁶¹School of Social and Health Sciences, Leeds Trinity University, Leeds, UK. ²⁶²TIPS - Network for Clinical Research in Psychosis; Stavanger University Hospital, Stavanger, Norway.

²⁶³NORMENT Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

²⁶⁴Department of Neurology, Medical University of Vienna, Vienna, Austria. ²⁶⁵Harvard Medical School Department of Psychiatry at Beth Israel Deaconess Medical Center, Boston MA, USA.

²⁶⁶Massachusetts Mental Health Center, Boston MA, USA. ²⁶⁷Lieber Institute for Brain Development, Baltimore MD, USA. ²⁶⁸Department of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands. ²⁶⁹Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles CA, USA. ²⁷⁰Department of Psychiatry, Washington University, St. Louis MO, USA. ²⁷¹Department of Psychiatry, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany. ²⁷²Berlin Institute of Health (BIH), Berlin, Germany. ²⁷³Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama Kanagawa, Japan. ²⁷⁴Université de Paris, Faculté de médecine, Hôpital Cochin-Tarnier, Paris, France. ²⁷⁵INSERM U1266, Institut de psychiatrie et de neurosciences, Paris, France. ²⁷⁶Bulgarian Academy of Science, Sofia, Bulgaria.

²⁷⁷Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy. ²⁷⁸Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. ²⁷⁹Department of Psychiatry, Faculty of Medicine, Istanbul University, Istanbul, Turkey. ²⁸⁰Division of Mental Health, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. ²⁸¹Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway. ²⁸²KU Leuven, Department of Neurosciences, Center for Clinical Psychiatry, Leuven, Belgium. ²⁸³Department of Psychiatry, Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland. ²⁸⁴Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. ²⁸⁵Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland. ²⁸⁶Department for Psychiatry and Psychotherapy, CCM Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

²⁸⁷Neuropsychiatric Epidemiology Research Unit, School of Population and Global Health, University of Western Australia, Perth WA, Australia. ²⁸⁸Centre for Clinical Research in Neuropsychiatry, The University of Western Australia, Perth WA, Australia. ²⁸⁹Sheba Medical Center, Tel Hashomer, Israel. ²⁹⁰School of Life and Environmental Sciences, University of Sydney, Sydney NSW, Australia. ²⁹¹Department of Psychiatry, GGz Centraal, The Netherlands.

²⁹²Stanley Neurovirology Laboratory, Johns Hopkins University School of Medicine, Baltimore MD, USA. ²⁹³Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto ON, Canada. ²⁹⁴Department of Psychiatry, University of Toronto, Toronto, ON, Canada. ²⁹⁵Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ²⁹⁶Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ²⁹⁷Department of Psychiatry, School of Medicine, Ankara University, Ankara, Turkey. ²⁹⁸Department of Psychiatry, Queens University Kingston, 191 Portsmouth Avenue, Kingston ON, Canada. ²⁹⁹Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City IA, USA. ³⁰⁰School of Nursing, Louisiana State University Health Sciences Center, New Orleans LA, USA. ³⁰¹Department of Psychiatry, University of California San Francisco, San Francisco CA, USA. ³⁰²Center for

Neuropsychiatric Research, National Health Research Institutes, Zhunan Town, Taiwan.

³⁰³Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. ³⁰⁴University of Sevilla, CIBERSAM, Sevilla, Spain. ³⁰⁵Hospital Universitario Virgen del Rocio, Department of Psychiatry, Universidad del Sevilla, Sevilla, Spain. ³⁰⁶Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide SA, Australia. ³⁰⁷Ramsay Health Care (SA) Mental Health, Ramsey MN, USA. ³⁰⁸Northern Adelaide Local Health Network. ³⁰⁹Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. ³¹⁰Genetic Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. ³¹¹Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan. ³¹²Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark. ³¹³Max Planck Institute of Psychiatry, Munich, Germany. ³¹⁴Munich Cluster for Systems Neurology, Munich, Germany. ³¹⁵Department of Health Data Science, University of Liverpool, Liverpool, UK. ³¹⁶Menzies Institute for Medical Research, University of Tasmania, Hobart TAS, Australia. ³¹⁷Mental Health Services in the Capital Region of Denmark, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark. ³¹⁸Rutgers University, Robert Wood Johnson Medical School, New Brunswick NJ, USA. ³¹⁹Rutgers University, New Jersey Medical School, Newark NJ, USA. ³²⁰Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland. ³²¹Department of Public Health, University of Helsinki, Helsinki, Finland. ³²²Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse NY, USA. ³²³Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany. ³²⁴Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University, Baltimore, MD, USA. ³²⁵Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge MA, USA. ³²⁶Regeneron Genetics Center, Orange CA, USA. ³²⁷College of Public Health, China Medical University, Taichung, Taiwan. ³²⁸State Key Laboratory of Genetic Engineering and Ministry of Education (MOE) Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center of Genetics and Development, Human Phenome Institute, School of Life Sciences, Fudan University, Shanghai, China. ³²⁹School of Life Science and Technology, ShanghaiTech University, Shanghai, China. ³³⁰Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, China. ³³¹Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden. ³³²Division of Psychiatry, Department of Mental Health Neuroscience, University College London, London, UK. ³³³Department of Psychiatry, San Cecilio University Hospital, University of Granada, Granada, Spain. ³³⁴Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. ³³⁵Department of Biomedicine, University of Basel, Basel, Switzerland. ³³⁶Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany. ³³⁷Eli Lilly and Company, Surrey, UK. ³³⁸Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, Dublin, Ireland. ³³⁹UCL Genetics Institute, UCL, London, UK. ³⁴⁰Centre for Psychiatry, Queen Mary University London, London, UK. ³⁴¹Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy. ³⁴²Dementia Research Institute, Cardiff University, Cardiff, UK. ³⁴³MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK. ³⁴⁴Department of Psychiatry, Phoenix VA Healthcare System, Phoenix AZ, USA. ³⁴⁵Banner-University Medical Center, Phoenix AZ, USA. ³⁴⁶Department of Human Molecular Genetics of the Institute of

Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of Sciences (IBG UFRC RAS), Ufa, Russia. ³⁴⁷Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation (BSMU), Ufa, Russia. ³⁴⁸Psychiatric Genetic Epidemiology and Neurobiology Laboratory (PsychGENe lab), Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse NY, USA. ³⁴⁹Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea. ³⁵⁰Institute of Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of Sciences (IBG UFRC RAS), Ufa, Russia. ³⁵¹Department of Psychiatry and Zilkha Neurogenetics Institute, Keck School of Medicine at University of Southern California, Los Angeles CA, USA. ³⁵²Department of Cell Biology, State University of New York, Downstate Medical Center, New York NY, USA. ³⁵³Department of Psychosis, Institute of Mental Health, Singapore, Singapore. ³⁵⁴Neuroscience and Mental Health, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. ³⁵⁵Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset NY, USA. ³⁵⁶Department of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, Hempstead NY, USA. ³⁵⁷Human Genetics, Genome Institute of Singapore, A*STAR, Singapore, Singapore. ³⁵⁸Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ³⁵⁹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffman-La Roche Ltd, Basel, Switzerland. ³⁶⁰Department of Preventative Medicine, Faculdade de Medicina FMUSP, University of Sao Paulo, Sao Paulo SP, Brazil. ³⁶¹Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK. ³⁶²Department of Psychiatry, University of Pittsburgh, Pittsburgh PA, USA. ³⁶³Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles CA, USA. ³⁶⁴Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. ³⁶⁵Early Clinical Development, Pfizer Worldwide Research and Development, Groton CT, USA. ³⁶⁶Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry Massachusetts General Hospital, Boston MA, USA. ³⁶⁷Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, USA. ³⁶⁸Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ³⁶⁹Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada, Spain. ³⁷⁰Institute of Neurosciences, Biomedical Research Center (CIBM), University of Granada, Granada, Spain. ³⁷¹Faculty of Science, Medicine and Health, School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong NSW, Australia. ³⁷²Illawarra Health and Medical Research Institute, Wollongong NSW, Australia. ³⁷³Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. ³⁷⁴Centre for PanorOmic Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ³⁷⁵State Key Laboratory of Brain and Cognitive Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ³⁷⁶Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ³⁷⁷Affiliated Hospital of Qingdao University and Biomedical Sciences Institute of Qingdao University (Qingdao Branch of SJTU Bio-X Institutes), Qingdao University, Qingdao, China. ³⁷⁸Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. ³⁷⁹Center for Behavioral Genomics; Department of Psychiatry; University of California, San Diego; La Jolla CA, USA. ³⁸⁰Institute of Genomic

Medicine, University of California, San Diego; La Jolla CA, USA. ³⁸¹University Medical Center Utrecht, Department of Psychiatry, Utrecht, The Netherlands. ³⁸²King's College London, King's Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, UK. ³⁸³Department of Psychiatry & Human Behavior, School of Medicine, University of California, Irvine CA, USA. ³⁸⁴Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark. ³⁸⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. ³⁸⁶Center for GeoGenetics, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark. ³⁸⁷The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen, Denmark. ³⁸⁸School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth WA, Australia. ³⁸⁹Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China. ³⁹⁰National Clinical Research Center for Mental Disorders & NHC Key Laboratory of Mental Health (Peking University) & Chinese Academy of Medical Sciences Research Unit (No.2018RU006), Beijing, China. ³⁹¹PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China. ³⁹²Mental Illness Research, Education, and Clinical Center (VISN 2 South), James J. Peters VA Medical Center, New York NY, USA. ³⁹³Oxford Health NHS Foundation Trust, Oxford, UK. ³⁹⁴Department of Clinical Genetics, Center for Neurogenomics and Cognitive Research, University Medical Center Amsterdam, Amsterdam, The Netherlands. ³⁹⁵Department of Functional Genomics, Faculty of Exact Science, Center for Neurogenomics and Cognitive Research, VU University Amsterdam and VU Medical Center, Amsterdam, The Netherlands. ³⁹⁶Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou Zhejiang, China.

*Lists of authors and their affiliations appears at the end of the paper.

†These authors contributed equally to this work.

‡These authors jointly supervised this work.

Indonesia Schizophrenia Consortium

Nan Dai^{397,398}, Qin Wenwen^{397,398}, DB Wildenauer^{397,398}, Feranindhya Agiananda³⁹⁹, Nurmiati Amir³⁹⁹, Ronald Antoni³⁹⁹, Tiana Arsianti³⁹⁹, Asmarahadi Asmarahadi³⁹⁹, H Diatri³⁹⁹, Prianto Djatmiko³⁹⁹, Irmansyah Irmansyah³⁹⁹, Siti Khalimah³⁹⁹, Irmia Kusumadewi³⁹⁹, Profitasari Kusumaningrum³⁹⁹, Petrin R Lukman³⁹⁹, Martina W Nasrun³⁹⁹, NS Safyuni³⁹⁹, Prasetyawan Prasetyawan³⁹⁹, G Semen³⁹⁹, Kristiana Siste³⁹⁹, Heriani Tobing³⁹⁹, Natalia Widiasih³⁹⁹, Tjhin Wiguna³⁹⁹, D Wulandari³⁹⁹, None Evalina³⁹⁹, AJ Hananto³⁹⁹, Joni H Ismoyo³⁹⁹, TM Marini³⁹⁹, Supiyani Henuhili³⁹⁹, Muhammad Reza³⁹⁹, Suzy Yusnadewi³⁹⁹

³⁹⁷Western Australian Institute for Medical Research and Centre for Medical Research, University of Western Australia, Nedlands WA, Australia. ³⁹⁸School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley WA, Australia. ³⁹⁹Department of Psychiatry, University of Indonesia, Jakarta, Indonesia.

PsychENCODE

Alexej Abyzov⁴⁰⁰, Schahram Akbarian⁴⁰¹, Allison Ashley-Koch⁴⁰², Harm van Bakel⁴⁰¹, Michael Breen⁴⁰¹, Miguel Brown⁴⁰³, Julien Bryois⁴⁰⁴, Becky Carlyle⁴⁰⁵, Alex Charney⁴⁰¹, Gerard Coetzee⁴⁰⁶, Gregory Crawford⁴⁰², Stella Dracheva⁴⁰¹, Prashant Emani⁴⁰⁵, Peggy Farnham⁴⁰⁶, Menachem Fromer¹⁴³, Timur Galeev⁴⁰⁵, Mike Gandal⁴⁰⁷, Mark Gerstein⁴⁰⁵, Gina Giase⁴⁰⁸, Kiran Girdhar⁴⁰¹, Fernando Goes⁴⁰⁹, Kay Grennan⁴⁰³, Mengting Gu⁴⁰⁵, Brittney Guerra⁴⁰⁵, Gamze Gursoy⁴⁰⁵, Gabriel Hoffman⁴⁰¹, Thomas Hyde²⁶⁷, Andrew Jaffe²⁶⁷, Shan Jiang⁴⁰⁸, Yan Jiang⁴⁰¹, Amira Kefi⁴⁰⁸, Yunjung Kim⁴¹⁰, Robert Kitchen⁴⁰⁵, James Knowles⁴¹¹, Fides Lay⁴⁰⁶, Donghoon Lee⁴⁰⁵, Mingfeng Li⁴⁰⁵, Chunyu Liu²⁴³, Shuang Liu⁴⁰⁵, Eugenio Mattei⁴¹², Fabio Navarro⁴⁰⁵, Xinghua Pan⁴⁰⁵, Mette A Peters⁴¹³, Dalila Pinto⁴⁰¹, Sirisha Pochareddy⁴⁰⁵, Damon Polioudakis⁴⁰⁷, Michael Purcaro⁴¹², Shaun Purcell⁴⁰¹, Henry Pratt⁴¹², Tim Reddy⁴⁰², Suhm Rhie⁴⁰⁶, Panagiotis Roussos⁴⁰¹, Joel Rozowsky⁴⁰⁵, Stephan Sanders⁴¹⁴, Nenad Sestan⁴⁰⁵, Anurag Sethi⁴⁰⁵, Xu Shi⁴⁰⁵, Annie Shieh⁴⁰⁸, Vivek Swarup⁴⁰⁷, Anna Szekely⁴⁰⁵, Daifeng Wang⁴⁰⁵, Jonathan Warrell⁴⁰⁵, Sherman Weissman⁴⁰⁵, Zhiping Weng⁴¹⁵, Kevin White⁴¹⁶, Jennifer Wiseman⁴⁰¹, Heather Witt⁴⁰⁶, Hyejung Won⁴⁰⁷, Shannon Wood⁴⁰⁶, Feinan Wu⁴⁰⁵, Xuming Xu⁴⁰⁵, Lijing Yao⁴⁰⁶, Peter Zandi⁴⁰⁹

⁴⁰⁰Mayo Clinic, Rochester MN, USA. ⁴⁰¹Mount Sinai, New York NY, USA. ⁴⁰²Duke University, Durham NC, USA. ⁴⁰³University of Chicago, Chicago IL, USA. ⁴⁰⁴Karolinska Institutet, Stockholm, Sweden. ⁴⁰⁵Yale University, New Haven CT, USA. ⁴⁰⁶University of Southern California, Los Angeles CA, USA. ⁴⁰⁷University of California, Los Angeles CA, USA. ⁴⁰⁸University of Illinois at Chicago, Chicago IL, USA. ⁴⁰⁹Johns Hopkins University, Baltimore MD, USA. ⁴¹⁰University of North Carolina - Chapel Hill, Chapel Hill NC, USA. ⁴¹¹SUNY Downstate Medical Center, New York NY, USA. ⁴¹²University of Massachusetts, Amherst MA, USA. ⁴¹³Sage Bionetworks, Seattle WA, USA. ⁴¹⁴University of California, San Francisco CA, USA. ⁴¹⁵University of Massachusetts Medical School, Worcester MA, USA. ⁴¹⁶Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Psychosis Endophenotypes International Consortium

Maria J Arranz^{417,418}, Steven Bakker¹⁷⁸, Stephan Bender^{419,420}, Elvira Bramon^{417,421}, David A Collier^{88,337}, Benedicto Crepo-Facorro^{110,422}, Jeremy Hall⁴²³, Conrad Iyegbe⁴¹⁷, Assen V Jablensky²⁸⁸, René Kahn¹⁷⁸, Stephen Lawrie⁴²⁴, Cathryn Lewis⁴¹⁷, Kuang Lin⁴¹⁷, Don H Linszen⁴²⁵, Ignacio Mata^{110,422}, Andrew McIntosh⁴²⁴, Robin M Murray⁴¹⁷, Roel A Ophoff⁴²⁶, Jim van Os^{427,428}, John Powell⁴¹⁷, Dan Rujescu^{429,430}, Muriel Walshe⁴¹⁷, Matthias Weisbrod⁴²⁰

⁴¹⁷King's College London, London, UK. ⁴¹⁸Fundació de Docència i Recerca Mútua de Terrassa, Universitat de Barcelona, Barcelona, Spain. ⁴¹⁹Child and Adolescent Psychiatry, University of Technology Dresden, Dresden, Germany. ⁴²⁰Section for Experimental Psychopathology, General Psychiatry, Heidelberg, Germany. ⁴²¹Institute of Cognitive Neuroscience, University College London, London, UK. ⁴²²University Hospital Marqués de Valdecilla, Instituto de Formación e Investigación Marqués de Valdecilla, University of Cantabria, Santander, Spain. ⁴²³Neuroscience and Mental Health Research Institute, Division of Psychiatry and Clinical Neuroscience, Cardiff University, Cardiff, UK. ⁴²⁴Division of Psychiatry, University of Edinburgh, Edinburgh, UK. ⁴²⁵Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁴²⁶Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles CA, USA. ⁴²⁷Maastricht University Medical Centre, South

Limburg Mental Health Research and Teaching Network, EURON, Maastricht, The Netherlands.
⁴²⁸Institute of Psychiatry, King's College London, London, UK. ⁴²⁹Department of Psychiatry,
University of Halle, Halle, Germany. ⁴³⁰Department of Psychiatry, University of Munich,
Munich, Germany.

The SynGO Consortium

Tilman Achsel⁴³¹, Maria Andres-Alonso⁴³², Claudia Bagni⁴³¹, Àlex Bayés⁴³³, Thomas Biederer⁴³⁴, Nils Brose⁴³⁵, Tyler C. Brown¹², John Jia En Chua⁴³⁶, Marcelo P. Coba⁴³⁷, L. Niels Cornelisse⁴³⁸, Arthur P.H. de Jong⁴³⁹, Jaime de Juan-Sanz⁴⁴⁰, Daniela C. Dieterich^{441,442}, Guoping Feng^{12,443}, Hana L. Goldschmidt⁴⁴⁴, Eckart D. Gundelfinger⁴⁴², Casper Hoogenraad⁴⁴⁵, Richard L. Huganir⁴⁴⁴, Steven E. Hyman^{12,446}, Cordelia Imig⁴⁴⁷, Reinhard Jahn⁴⁴⁸, Hwajin Jung⁴⁴⁹, Pascal S. Kaeser⁴⁵⁰, Eunjoon Kim⁴⁴⁹, Frank Koopmans³⁹⁵, Michael R. Kreutz⁴³², Noa Lipstein⁴⁵¹, Harold D. MacGillavry⁴³⁹, Robert Malenka⁴⁵², Peter S. McPherson⁴⁵³, Vincent O'Connor⁴⁵⁴, Rainer Pielot^{441,442}, Timothy A. Ryan⁴⁵⁵, Dnyanada Sahasrabudhe³⁹⁵, Carlo Sala⁴⁵⁶, Morgan Sheng¹², Karl-Heinz Smalla^{441,442}, August B Smit⁴⁵⁷, Thomas C. Südhof⁴⁵⁸, Paul D. Thomas⁴⁵⁹, Ruud F. Toonen³⁹⁵, Jan R.T. van Weering⁴³⁸, Matthijs Verhage³⁹⁵, Chiara Verpelli⁴⁵⁶

⁴³¹Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.
⁴³²RG Neuroplasticity, Leibniz Institute for Neurobiology, Magdeburg, Germany. ⁴³³Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau, Barcelona, Spain.
⁴³⁴Department of Neurology, Yale School of Medicine, New Haven CT, USA. ⁴³⁵Department of Molecular Neurobiology, Max Planck Institute of Experimental Medicine, Göttingen, Germany.
⁴³⁶LSI Neurobiology Programme, National University of Singapore, Singapore. ⁴³⁷Zilkha Neurogenetic Institute and Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles CA, USA. ⁴³⁸Functional Genomics section, Department Human Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam University Medical Center, Amsterdam, The Netherlands. ⁴³⁹Cell Biology, Neurobiology and Biophysics, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands. ⁴⁴⁰Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France. ⁴⁴¹Institute for Pharmacology and Toxicology, Medical Faculty Otto-von-Guericke University Magdeburg, Magdeburg, Germany. ⁴⁴²Leibniz Institute for Neurobiology (LIN), Magdeburg, Germany.
⁴⁴³McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology (MIT), Cambridge MA, USA. ⁴⁴⁴Solomon H. Snyder Department of Neuroscience Kavli Neuroscience Discovery Institute The Johns Hopkins University School of Medicine Baltimore, Baltimore MD, USA. ⁴⁴⁵Department of Neuroscience, Genentech, Inc., South San Francisco CA, USA. ⁴⁴⁶Department of Stem Cell and Regenerative Biology, Harvard University; 7 Divinity Avenue, Cambridge MA 02138. ⁴⁴⁷Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark. ⁴⁴⁸Laboratory of Neurobiology, Max-Planck Institute for Biophysical Chemistry, Göttingen, Germany. ⁴⁴⁹Center for Synaptic Brain Dysfunctions, Institute for Basic Science (IBS), Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea. ⁴⁵⁰Department of Neurobiology, Harvard Medical School, Boston MA, USA. ⁴⁵¹Department of Molecular Physiology and Cell Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin,

Germany. ⁴⁵²Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford CA, USA. ⁴⁵³Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. ⁴⁵⁴Biological Sciences, University of Southampton, Southampton, UK. ⁴⁵⁵Department of Biochemistry, Weill Cornell Medicine, New York NY, USA. ⁴⁵⁶CNR Neuroscience Institute, Milan, Italy. ⁴⁵⁷Dept. of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ⁴⁵⁸Department of Molecular & Cellular Physiology, Howard Hughes Medical Institute, Stanford University, Stanford CA, USA. ⁴⁵⁹Division of Bioinformatics, Dept. of Preventive Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles CA, USA.

Schizophrenia Working Group of the Psychiatric Genomics Consortium

Vassily Trubetskoy¹, Antonio F Pardiñas², Georgia Panagiotaropoulou¹, Swapnil Awasthi¹, Tim B Bigdeli^{5,6,7}, Charlotte A Dennison², Lynsey S Hall², Max Lam^{12,13,14}, Oleksandr Frei^{16,17,18}, Alexander L Richards², Jakob Grove^{22,23,24}, Zhiqiang Li^{26,27}, Mark Adams³⁰, Ingrid Agartz^{16,31,32}, Elizabeth G Atkinson^{10,12}, Esben Agerbo^{22,33}, Mariam Al Eissa³⁴, Margot Albus³⁵, Madeline Alexander³⁶, Behrooz Z Alizadeha^{37,38}, Köksal Alptekin^{39,40}, Thomas D Als^{22,23,24}, Farooq Amin⁴¹, Volker Arolt⁴², Manuel Arrojo⁴³, Lavinia Athanasiu^{16,17}, Maria Helena Azevedo⁴⁴, Silviu A Bacanu⁴⁵, Nicholas J Bass³⁴, Martin Begemann⁴⁶, Richard A Belliveau¹², Judit Bene⁴⁷, Beben Benyamini^{48,49,50}, Sarah E Bergen⁸, Giuseppe Blasi⁵¹, Julio Bobes^{52,53,54}, Stefano Bonassi⁵⁵, Alice Braun¹, Rodrigo Affonseca Bressan^{56,57}, Evelyn J Bromet⁵⁸, Richard Bruggeman^{37,59}, Peter F Buckley⁶⁰, Randy L Buckner⁶¹, Jonas Bybjerg-Grauholm^{22,62}, Wiepke Cahn^{63,64}, Murray J Cairns^{65,66,67}, Monica E Calkins⁶⁸, Vaughan J Carr^{69,70,71}, David Castle^{72,73}, Stanley V Catts^{74,75}, Kimberley D Chambert¹², Raymond CK Chan^{76,77}, Boris Chaumette^{78,79}, Wei Cheng⁸⁰, Eric FC Cheung⁸¹, Siow Ann Chong^{13,82}, David Cohen^{83,84,85}, Angèle Consoli^{83,84}, Quirino Cordeiro⁸⁶, Javier Costas⁸⁷, Charles Curtis^{88,89}, Michael Davidson⁹⁰, Kenneth L Davis⁹¹, Lieuwe de Haan^{92,93}, Franziska Degenhardt⁹⁴, Lynn E DeLisi^{19,95}, Ditte Demontis^{22,23,24}, Faith Dickerson⁹⁶, Dimitris Dikeos⁹⁷, Timothy Dinan^{98,99}, Srdjan Djurovic^{100,101}, Jubao Duan^{102,103}, Giuseppe Ducci¹⁰⁴, Johan G Eriksson^{106,107,108}, Lourdes Fañanás^{109,110}, Stephen V Faraone¹¹¹, Alessia Fiorentino³⁴, Andreas Forstner^{94,112}, Josef Frank¹¹³, Nelson B Freimer^{114,115}, Menachem Fromer¹¹⁶, Alessandra Frustaci¹¹⁷, Ary Gadelha^{56,57}, Giulio Genovese¹², Elliot S Gershon¹¹⁸, Marianna Giannitelli^{83,84}, Ina Giegling¹¹⁹, Paola Giusti-Rodríguez¹²⁰, Stephanie Godard¹²¹, Jacqueline I Goldstein¹⁰, Javier González Peñas^{110,122}, Ana González-Pinto^{110,123}, Srihari Gopal¹²⁴, Jacob Gratten^{3,125}, Michael F Green^{126,127}, Tiffany A Greenwood¹²⁸, Olivier Guillin^{129,130,131}, Sinan Gülöksüz^{132,133}, Raquel E Gur⁶⁸, Ruben C Gur⁶⁸, Blanca Gutiérrez¹³⁴, Eric Hahn¹³⁵, Hakon Hakonarson¹³⁶, Vahram Haroutunian^{91,137,138}, Annette M Hartmann¹¹⁹, Carol Harvey^{72,139}, Caroline Hayward¹⁴⁰, Frans A Henskens¹⁴¹, Stefan Herms¹⁴², Per Hoffmann¹⁴², Daniel P Howrigan^{10,143}, Masashi Ikeda¹⁴⁴, Conrad Iyegbe¹⁴⁵, Inge Joa¹⁴⁶, Antonio Julià¹⁴⁷, Anna K Kähler⁸, Tony Kam-Thong¹⁴⁸, Yoichiro Kamatani^{149,150}, Sena Karachanak-Yankova^{151,152}, Oussama Kebir⁷⁸, Matthew C Keller¹⁵³, Brian J Kelly¹⁴¹, Andrey Khrunin¹⁵⁴, Sung-Wan Kim¹⁵⁵, Janis Klovins¹⁵⁶, Nikolay Kondratiev¹⁵⁷, Bettina Konte¹¹⁹, Julia Kraft^{1,158}, Michiaki Kubo¹⁵⁹, Vaidutis Kučinskas¹⁶⁰, Zita Ausrele Kučinskiene¹⁶⁰, Agung Kusumawardhani¹⁶¹, Hana Kuzelova-Ptackova¹⁶², Stefano Landi¹⁶³, Laura C Lazzeroni^{164,165}, Phil H Lee^{12,166}, Sophie E Legge², Douglas S Lehrer¹⁶⁷, Rebecca Lencer⁴²,

Bernard Lerer¹⁶⁸, Miaoxin Li¹⁶⁹, Jeffrey Lieberman¹⁷⁰, Gregory A Light^{128,171}, Svetlana Limborska¹⁵⁴, Chih-Min Liu^{172,173}, Jouko Lönnqvist^{174,175}, Carmel M Loughland¹⁷⁶, Jan Lubinski¹⁷⁷, Jurjen J Luykx^{132,178,179,180}, Amy Lynham², Milan Macek Jr¹⁸¹, Andrew Mackinnon^{182,183}, Patrik KE Magnusson⁸, Brion S Maher¹⁸⁴, Wolfgang Maier¹⁸⁵, Dolores Malaspina^{91,186}, Jacques Mallet¹⁸⁷, Stephen R Marder¹⁸⁸, Sara Marsal¹⁴⁷, Alicia R Martin^{10,12,189}, Lourdes Martorell¹⁹⁰, Manuel Mattheisen^{23,191,192,193}, Robert W McCarley^{194,195}, Colm McDonald¹⁹⁶, John J McGrath^{33,197,198}, Helena Medeiros^{199,200}, Sandra Meier^{191,201}, Bela Melegh²⁰², Ingrid Melle^{16,17}, Raquelle I Mesholam-Gately^{19,203}, Andres Metspalu²⁰⁴, Patricia T Michie²⁰⁵, Lili Milani²⁰⁴, Vihra Milanova²⁰⁶, Marina Mitjans⁴⁶, Espen Molden^{207,208}, Esther Molina²⁰⁹, María Dolores Molto^{110,210,211}, Valeria Mondelli^{89,212}, Carmen Moreno^{110,122}, Christopher P Morley²¹³, Gerard Muntané^{190,214}, Kieran C Murphy²¹⁵, Inez Myin-Germeys²¹⁶, Igor Nenadic^{217,218}, Gerald Nestadt²¹⁹, Liene Nikitina-Zake¹⁵⁶, Cristiano Noto^{56,57}, Keith H Nuechterlein¹²⁶, Niamh Louise O'Brien³⁴, F Anthony O'Neill²²⁰, Sang-Yun Oh^{221,222}, Ann Olincy²²³, Vanessa Kiyomi Ota^{57,224}, Christos Pantelis^{139,225,226,227}, George N Papadimitriou⁹⁷, Mara Parellada^{110,122}, Tiina Paunio^{228,229}, Renata Pellegrino¹³⁶, Sathish Periyasamy^{197,230}, Diana O Perkins²³¹, Bruno Pfuhlmann²³², Olli Pietiläinen^{12,233,234}, Jonathan Pimm³⁴, David Porteous²³⁵, John Powell²³⁶, Diego Quattrone^{88,89,237}, Digby Quested^{238,239}, Allen D Radant^{240,241}, Antonio Rampino⁵¹, Mark H Rapaport²⁴², Anna Rautanen¹⁴⁸, Abraham Reichenberg⁹¹, Cheryl Roe²⁴³, Joshua L Roffman²⁴⁴, Julian Roth²⁴⁵, Matthias Rothermundt⁴², Bart PF Rutten¹³², Safaa Saker-Delye²⁴⁶, Veikko Salomaa²⁴⁷, Julio Sanjuan^{110,211,248}, Marcos Leite Santoro^{57,224}, Adam Savitz¹²⁴, Ulrich Schall^{166,249}, Rodney J Scott^{65,250,251}, Larry J Seidman^{19,203}, Sally Isabel Sharp³⁴, Jianxin Shi²⁵², Larry J Siever^{91,253}, Kang Sim^{256,257,258}, Nora Skarabis¹, Petr Slominsky¹⁵⁴, Hon-Cheong So^{259,260}, Janet L Sobell¹⁹⁹, Erik Söderman³², Helen J Stain^{261,262}, Nils Eiel Steen^{17,263}, Agnes A. Steixner-Kumar⁴⁶, Elisabeth Stögmann²⁶⁴, William S Stone^{265,266}, Richard E Straub²⁶⁷, Fabian Streit¹¹³, Eric Strengman²⁶⁸, T Scott Stroup¹⁷⁰, Mythily Subramaniam^{13,82}, Catherine A Sugar^{126,269}, Jaana Suvisaari²⁴⁷, Dragan M Svrakic²⁷⁰, Neal R Swerdlow¹²⁸, Jin P Szatkiewicz¹²⁰, Thi Minh Tam Ta^{271,272}, Atsushi Takahashi^{132,273}, Chikashi Terao²⁷³, Florence Thibaut^{274,275}, Draga Toncheva^{151,276}, Paul A Tooney^{65,66,67}, Silvia Torretta⁵¹, Sarah Tosato²⁷⁷, Gian Battista Tura²⁷⁸, Bruce I Turetsky⁶⁸, Alp Üçok²⁷⁹, Arne Vaaler^{280,281}, Therese van Amelsvoort^{89,132}, Ruud van Winkel^{132,282}, Juha Veijola^{283,284}, John Waddington²⁸⁵, Henrik Walter²⁸⁶, Anna Waterreus^{287,288}, Bradley T Webb⁴⁵, Mark Weiser²⁸⁹, Nigel M Williams², Stephanie H Witt¹¹³, Brandon K Wormley⁴⁵, Jing Qin Wu²⁹⁰, Zhida Xu²⁹¹, Robert Yolken²⁹², Clement C Zai^{293,294}, Wei Zhou²⁷, Feng Zhu^{295,296}, Fritz Zimprich²⁶⁴, Eşref Cem Atbaşoğlu^{186,297}, Muhammad Ayub²⁹⁸, Alessandro Bertolino⁵¹, Donald W Black²⁹⁹, Nicholas J Bray², Gerome Breen⁸⁸, Nancy G Buccola³⁰⁰, William F Byerley³⁰¹, Wei J Chen^{302,303}, C Robert Cloninger²⁷⁰, Benedicto Crespo-Facorro^{304,305}, Gary Donohoe¹⁹⁶, Robert Freedman²²³, Cherrie Galletly^{306,307,308}, Massimo Gennarelli^{309,310}, David M Hougaard^{22,62}, Hai-Gwo Hwu^{173,311}, Assen V Jablensky²⁸⁸, Steven A McCarroll¹², Jennifer L Moran^{12,244}, Ole Mors^{22,312}, Preben B Mortensen^{22,33}, Bertram Müller-Myhsok^{313,314,315}, Amanda L Neil³¹⁶, Merete Nordentoft^{22,317}, Michele T Pato^{318,319}, Tracey L Petryshen¹⁶⁶, Ann E Pulver²¹⁹, Thomas G Schulze^{193,322,323,324}, Jeremy M Silverman^{91,253}, Jordan W Smoller^{12,166}, Eli A Stahl^{116,325,326}, Debby W Tsuang^{240,241}, Elisabet Vilella¹⁹⁰, Shi-Heng Wang³²⁷, Shuhua Xu^{328,329,330}, Rolf Adolfsson³³¹, Celso Arango^{110,122}, Bernhard T Baune^{42,226,227}, Sintia Iole Belangero^{57,224}, Anders D Børglum^{22,23,24}, David Braff^{128,171}, Elvira Bramon³³², Joseph D Buxbaum⁹¹, Dominique Campion^{129,130}, Jorge A Cervilla³³³, Sven Cichon^{334,335,336}, David A Collier³³⁷, Aiden Corvin³³⁸,

Marta Di Forti^{88,89,237}, Enrico Domenici³⁴¹, Hannelore Ehrenreich⁴⁶, Valentina Escott-Price^{342,343}, Tõnu Esko^{204,325}, Ayman H Fanous^{7,344,345}, Anna Gareeva^{346,347}, Micha Gawlik²⁴⁵, Pablo V Gejman^{102,103}, Michael Gill³³⁸, Stephen J Glatt³⁴⁸, Vera Golimbet¹⁵⁷, Kyung Sue Hong³⁴⁹, Christina M Hultman⁸, Steven E Hyman^{12,233}, Nakao Iwata¹⁴⁴, Erik G Jönsson^{32,263}, René S Kahn^{63,91}, James L Kennedy^{293,294}, Elza Khusnutdinova^{347,350}, George Kirov², James A Knowles^{351,352}, Marie-Odile Krebs⁷⁸, Claudine Laurent-Levinson^{83,84}, Jimmy Lee^{353,354}, Todd Lencz^{14,355,356}, Douglas F Levinson¹⁶⁴, Qingqin S Li¹²⁴, Jianjun Liu^{357,358}, Anil K Malhotra^{14,355,356}, Dheeraj Malhotra³⁵⁹, Andrew McIntosh³⁰, Andrew McQuillin³⁴, Paulo R Menezes³⁶⁰, Vera A Morgan^{287,288}, Derek W Morris¹⁹⁶, Bryan J Mowry^{197,230}, Robin M Murray^{89,361}, Vishwajit Nimgaonkar³⁶², Markus M Nöthen⁹⁴, Roel A Ophoff^{114,363,364}, Sara A Paciga³⁶⁵, Aarno Palotie^{234,366,367}, Carlos N Pato^{318,319}, Shengying Qin^{27,368}, Marcella Rietschel¹¹³, Brien P Riley⁴⁵, Margarita Rivera^{369,370}, Dan Rujescu¹¹⁹, Meram C Saka²⁹⁷, Alan R Sanders^{102,103}, Sibylle G Schwab^{371,372}, Alessandro Serretti³⁷³, Pak C Sham^{374,375,376}, Yongyong Shi^{27,377}, David St Clair³⁷⁸, Ming T Tsuang^{379,380}, Jim van Os^{381,382}, Marquis P Vawter³⁸³, Daniel R Weinberger²⁶⁷, Thomas Werge^{384,385,386,387}, Dieter B Wildenauer³⁸⁸, Xin Yu^{389,390}, Weihua Yue^{389,390,391}, Peter A Holmans², Panos Roussos^{28,392}, Evangelos Vassos^{88,89,393}, Danielle Posthuma³⁹⁵, Ole A Andreassen^{16,17}, Kenneth S Kendler⁴⁵, Michael J Owen², Naomi R Wray^{3,197}, Mark J Daly^{10,143,234}, Hailiang Huang^{10,12,189}, Benjamin M Neale^{10,12}, Patrick F Sullivan^{8,120,231}, Stephan Ripke^{1,10,367}, James TR Walters², Michael C O'Donovan²